



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 :

G01N 33/569, 33/557, A61K 39/00,
C07K 14/00, C12N 15/00, 15/83

A1

(11) International Publication Number:

WO 97/41440

(43) International Publication Date:

6 November 1997 (06.11.97)

(21) International Application Number: PCT/NL97/00229

(22) International Filing Date: 28 April 1997 (28.04.97)

(30) Priority Data:

96201145.8 26 April 1996 (26.04.96) EP

(34) Countries for which the regional or
international application was filed: NL et al.

96203670.3 23 December 1996 (23.12.96) EP

(34) Countries for which the regional or
international application was filed: NL et al.(71) Applicants (for all designated States except US): RIJKSUNI-
VERSITEIT TE LEIDEN [NL/NL]; Stationsweg 46, NL-
2312 AV Leiden (NL). SEED CAPITAL INVESTMENTS
(SCI) B.V. [NL/NL]; Bernadottelaan 15, NL-3527 GA
Utrecht (NL).

(72) Inventors; and

(75) Inventors/Applicants (for US only): VAN DER BURG, Sjo-
erd, Henricus [NL/NL]; Schuberthof 15, NL-2742 BT
Waddinxveen (NL). KAST, Wybe, Martin [NL/US]; 201
Hill Road, Willowbrook, IL 60150 (US). TOES, Reinaldus,
Everardus, Maria [NL/NL]; Marco Polostraat 73 III, NL-
1057 WN Amsterdam (NL). OFFRINGA, Rienk [NL/NL];
Stieltjesstraat 63, NL-2313 SJ Leiden (NL). MELIEF, Cor-nelius, Johannes, Maria [NL/NL]; Wilhelminapark 33, NL-
2012 KC Haarlem (NL).(74) Agent: SMULDERS, Th., A., H., J.; Vereenigde Octrooibu-
reaux, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,
GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT,
UA, UG, US, UZ, VN, YU, ARIPO patent (GH, KE, LS,
MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ,
MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI
patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
SN, TD, TG).

Published

With international search report.

Before the expiration of the time limit for amending the
claims and to be republished in the event of the receipt of
amendments.(54) Title: METHODS FOR SELECTING AND PRODUCING T CELL PEPTIDE EPITOPES AND VACCINES INCORPORATING
SAID SELECTED EPITOPES

(57) Abstract

The present invention relates to the field of molecular biology and immunology. In particular it relates to vaccines and methods for providing vaccines which elicit immune responses when administered to a mammal, in particular a human. The preferred elicited immune response is a T cell response, elicited by peptide T cell epitopes. These vaccines find their application in many fields ranging from cancer treatments to treatments of prophylaxis of infectious diseases such as Aids. The present invention provides novel methods for selecting the peptide sequences from an intact antigen which will lead to a proper (T cell) immune response upon administration in a suitable vehicle. The epitopes and vaccines are, of course, also part of the present invention.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

Title: Methods for selecting and producing T cell peptide epitopes and vaccines incorporating said selected epitopes.

§1 Field of the invention

The present invention relates to the field of molecular biology and immunology. In particular it relates to vaccines and methods for providing vaccines which elicit immune responses when administered to a mammal, in particular a human. The preferred elicited immune response is a T cell response, elicited by peptide T cell epitopes. These vaccines find their application in many fields ranging from cancer treatments to treatments or prophylaxis of infectious diseases such as Aids. The present invention provides novel methods for selecting the peptide sequences from an intact antigen which will lead to a proper (T cell) immune response upon administration in a suitable vehicle. The epitopes and vaccines are, of course, also part of the present invention.

§2 Background of the invention

Virtually all currently available vaccines are not rationally designed in the sense of detailed knowledge of minimal essential epitopes and the rules of antigen processing and presentation. Rather, the available vaccines are based on empirical knowledge of protection. A major objective of the present invention is to develop a new generation of more rationally designed vaccines which are effective, safe, easy to manufacture and standardise, stable, inexpensive and associated with long lasting protection. This objective is achieved by employing our knowledge on the biochemistry of antigen processing and presentation in general, and in dendritic cells in particular, in the selection of peptide epitopes. Subsequently, selected peptide epitopes are incorporated into various types of vaccines and tested for efficacy in for instance HLA-transgenic mouse models.

SUBSTITUTE SHEET (RULE 26)

The selection of peptide epitopes for a given combination of antigen and HLA class I molecule according to the invention may be divided in the following subsequent steps:

- 5 1. Computer prediction of peptides within the primary sequence of the antigen that are most likely to bind to the HLA class I molecule concerned, by comparison with the relevant motif for MHC class I binding (1).
2. Measurement of the actual binding of the selected
10 peptides to the MHC molecule concerned using assays that determine HLA-peptide binding and stability of the HLA-peptide complex (2, 3) (Examples 1 and 2 herein).
3. Screening of the peptides (selected by steps 1 & 2) and their flanking sequences (in the context of the intact
15 antigen) for compliance with the rules for proteasome cleavage of natural protein sequences (4).
4. Screening of the peptides (selected by steps 1 & 2) and their flanking sequences (in the context of the intact antigen) for compliance with the rules for effective peptide
20 transport and loading into HLA class I molecules (5).

Selected peptide epitopes (see steps 1-4) are incorporated into the following prototype vaccines, the efficacy of which is compared in the appropriate HLA
25 transgenic mouse model:

- i. Mixture of synthetic peptides in adjuvants.
- ii. Mixture of synthetic peptides loaded onto dendritic cells.
- iii. Recombinant protein, synthesized in - and purified
30 from - E.coli, consisting of a string bead arrangement of peptide-epitopes which are separated from each other by proteolytic cleavage sites. Protein administered in adjuvants.
- iv. Recombinant protein (see iii; mannosylated) loaded
35 onto dendritic cells.
- v. Recombinant DNA construct (naked DNA) that encodes string-beads of peptide epitopes which are

SUBSTITUTE SHEET (RULE 26)

- separated by proteolytic cleavage sites.
- vi. Recombinant Canary pox virus that encodes string-beads of peptide epitopes which are separated by proteolytic cleavage sites.
- 5 vii. Recombinant human adenovirus that encodes string-beads of peptide epitopes which are separated by proteolytic cleavage sites.

Efficacy of the various vaccination protocols is assayed
10 by restimulation in mixed lymphocyte cultures of spleen cells of the immunized animals with autologous LPS B-cell blasts that are loaded with the relevant peptide(s), followed by measurement of the reactivity of the resulting T cell cultures against target cells that either present synthetic
15 peptides or the naturally processed epitopes.

The peptide epitopes are also used for the induction of antigen-specific T cell activity in HLA-transgenic mixed lymphocyte cultures in vitro. To that end, the peptide(s) of choice are loaded onto either syngeneic LPS B-cell blasts or
20 dendritic cells. These cells are irradiated and used as stimulator cells with nylonwool passed spleen cells of HLA-transgenic mice. After in vitro stimulation for one or two weeks, the reactivity of the resulting T cell populations can be measured against target cells that either present
25 synthetic peptides or the naturally processed epitopes.

Rational design of vaccines has clear advantages. Safety is one. For example DNA or viral vector vaccines for HPV16 E6 and E7 are intrinsically unsafe if such vaccines contain functional oncogenes, but safe if the DNA or viral vector
30 encodes string beads of epitopes, a preferred embodiment of the present invention. Additional advantages are effectiveness and simplicity. Only effectively immunizing components are included. Irrelevant sequences are deleted, easing manufacture and standardization, enhancing stability
35 and decreasing cost.

The design of effective T cell epitope vaccines hinges on the accurate selection of immunogenic peptides. By means

SUBSTITUTE SHEET (RULE 26)

of the current invention. (a method that analyzes the stability of peptide-MHC complexes at the surface of antigen-presenting cells) we have considerably improved the selection procedure. Moreover, we have also significantly improved the procedure by which poly- T cell-epitope-containing vaccines induce strong anti-tumor and anti-viral immune responses.

The present invention thus provides a method for the selection of T cell peptide epitopes present in polypeptide antigens comprising identification of peptides in the primary sequence of the antigen having a binding motif and size for binding to a HLA class I molecule, measuring the binding of said identified peptides to MHC class I molecules, whereby the stability of the complex of the peptide and the MHC class I molecule is measured on intact cells carrying said MHC class I molecule at their surfaces. Moreover, the present invention provides a new method for the application of identified T cell epitopes comprising incorporation of a multitude of T cell epitopes in a string-of-bead construct, in which the T cell epitopes preferably are linked to each other by a spacer-sequence that ensures efficient processing and presentation of the relevant T cell epitopes.

§3 Summary of the invention

Peptide-binding to MHC under physiological conditions is governed by dynamic balance between association and dissociation of the MHC-peptide complexes. Both the capacity of a peptide to bind to an MHC molecule and the stability of the resulting MHC-peptide complex over time will determine the amount of a given peptide-MHC complex at the surface of a target/stimulator cells and, thereby, the chance that this configuration will be detected by responding T lymphocytes. Several assays have been set up to measure these parameters in the context of the human and the murine immune system. These assays are especially suitable for measuring peptide binding and stability of peptide-MHC complexes in the context of various HLA class I molecules:

- i. The T2-assay, that measures binding of peptides to empty MHC class I MHC molecules at the surface of the processing defective cell line 174CEM.T2 (T2) (2).
- ii. An assay that measures binding of peptides to soluble class I MHC molecules that have been isolated from appropriate cell lines (6).
- iii. An assay that measures binding of peptides to soluble class I MHC molecules that have been isolated as recombinant proteins from E. coli cultures that overexpress these proteins (7, 8).
- iv. An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells (3) (Example 1 herein).
- v. An HLA class I peptide-binding assay that measures the stability of class I MHC-peptide complexes on intact human B cells (a major object of the present invention; see Examples 2 and 3 herein).

In one important embodiment of the present invention the latter assay is provided: a novel assay that measures MHC-peptide complex stability on intact human B cells. The binding affinity of peptides to MHC molecules under physiological conditions is a dynamic equilibrium between association and dissociation of the tri-molecular complex of peptide, MHC class I heavy chain and β 2-microglobulin. Currently, the affinity of peptides for a given class I molecule is based on assays that employ either cell-bound MHC class I molecules or purified "cell-free" MHC class I molecules. Affinity is measured by comparative capacity of peptides to upregulate MHC class I molecules on the surface of processing defective cells (2) or by their ability to compete with high affinity reference peptides (3, 9, 10). However, these assays hardly take into account the stability of peptide-MHC complexes under physiological conditions due to short incubation time, continuous presence of high concentrations of exogenous peptide, or reduced temperature. Recently, we have measured the fate of existing MHC-peptide complexes over time under more physiological conditions.

SUBSTITUTE SHEET (RULE 26)

Peptides displaying comparable binding affinities as measured in previous assays, showed marked differences with respect to the stability of the peptide-MHC complexes. Moreover, stability of the peptide-MHC complex correlated better with
5 the immunogenicity of the peptide than binding affinity (see Examples 2 and 3 of this patent application).

Examples of self peptides displaying low binding affinity that represent immunogenic T cell epitopes are peptides derived from MART-1 (AAGIGILTV / ILTVILGVL) (11),
10 Pmel17/gp100 (YLEPGPVTA) (12) and p53 (LLGRNSFEV) (13). These peptides were enclosed in this category based on results obtained in classical binding assays. However, measurement of the stability of the relevant peptide-MHC complexes revealed that the stability of these complexes is comparable to that
15 of known epitopes of viral origin (see Examples 2 and 3 of this patent application). Therefore, these peptides, although somewhat sluggish in mounting the MHC molecule, should not be regarded as displaying a low affinity for the presenting MHC molecule. This notion confirms that, in addition to peptide
20 binding affinity, stability of the peptide-MHC complex is an important parameter for the identification of immunogenic peptide-epitopes. As MHC-peptide complex stability correlates even better with the immunogenicity of the peptide than binding affinity, assays measuring complex stability
25 represent an important and indispensable new step in the sequence of procedures that is used to identify immunogenic peptide epitopes from primary amino acid sequences.

Another important embodiment of the present invention is provided by the innovative method that induces T cell
30 reactivity against multiple pre-selected T cell epitopes by immunization with a recombinant adenovirus (rAd) vector that contains multiple T cell epitopes in a string-of-bead fashion in which the T cell epitopes are linked to each other by proteolytic cleavage sites. The linkage of T cell epitopes by
35 spacer sequences ensures that the T cell epitopes are efficiently processed and presented to T cell. Therefore, the incorporation of multiple T cell epitopes spaced by linker-

SUBSTITUTE SHEET (RULE 26)

sequences preferably into recombinant adenovectors represents an important and powerful new approach for the induction of strong anti-viral and anti-tumor T cell immunity that is directed against multiple T cell targets.

5

§4 Detailed description of the invention

Herein we describe an assay that measures the stability of peptide-MHC complexes at the surface of human B cell lines. This assay, which is used to identify immunogenic peptide-epitopes, constitutes a major step forward on the road towards rational vaccine design. The novel methodology described herein is based on a binding assay that measures peptide binding on intact human B cells. This assay is, therefore, separately described in the following paragraph (§4.1). This binding assay has been published previously. The stability assay, which utilizes an innovative combination of steps is subsequently described (§4.2). The part of the patent application describing a vaccination strategy using rAd harbouring string-of-bead constructs encoding several pre-selected T cell epitopes is given in § 4.5.

20

§4.1 An HLA class I peptide-binding assay based on competition for binding to class I molecules on intact human B cells.

Peptide-binding assays employ either cell-bound MHC class I molecules (2, 3) or purified "cell-free" MHC class I molecules (6). Assays relying on cell-bound MHC class I molecules are based on upregulation (2) or reconstitution of MHC class I molecules (3) as detected by MHC class I conformation-specific antibodies. Cell-free systems are quantitative and make use of purified MHC molecules to which labeled reference peptides are bound in a competition set-up (6). Purification of MHC class I molecules, however, is laborious and conformational changes may occur during purification and/or storage. The peptide binding assay we use to identify peptides which bind to various HLA class I molecules utilizes fluorescein-labeled reference peptides

35

SUBSTITUTE SHEET (RULE 26)

that bind to HLA class I molecules on HLA-homozygous B-cell lines, of which the bound peptides have been removed by mild-acid treatment. The use of intact human B cells as tools in peptide binding assays has several clear advantages:

- 5 * EBV-transformed B cells can be easily grown to high numbers without the use of exclusive (=expensive) tissue culture media or growth factors.
- * EBV-transformed B cells express high levels of class I MHC; no treatment with lymphokines such as IFN γ is needed to reach
10 these high expression levels.
- * the mild-acid treated B cells are easily prepared; including harvesting of the B cells from cultures, the amount of stripped B cells needed for an average assay will be ready for use within 30 minutes.
- 15 * an almost infinite repertoire of EBV-transformed human B cell lines, expressing various combinations of class I MHC molecules, is available in many laboratories throughout the world
- * when necessary, new EBV-transformed B cell lines can
20 readily be made within one month. EBV-transformation of human B cells is a very straightforward procedure that is routinely performed in many laboratories throughout the world.

We have shown that the binding of fluorescein-labeled peptides to these peptide-stripped HLA class I molecules is
25 specific and allows the semi-quantitative determination of the binding-capacity of peptides. The kinetics of peptide-binding to these peptide-stripped HLA class I molecules is comparable to that of soluble HLA class I molecules and independent of biosynthesis of new HLA class I molecules.

30 This assay was optimized and validated with peptides of known binding capacity to either HLA-A*0101, HLA-A*0201, HLA-A*0301, HLA-A*1101 or HLA-A*2401 (3, 6) (our additional unpublished data). Furthermore, this assay was among others applied in the identification of potential HLA-A0301-
35 restricted conserved CTL epitopes derived from HIV-1 polymerase (3).

SUBSTITUTE SHEET (RULE 26)

Example 1.

Validation of a peptide-binding assay employing the HLA-A*0201 and A*0301 molecules on intact human B cells (adapted from (3)).

5

Materials and methods*Cell lines*

The EBV transformed B cell lines (B-LCL) used for the competition assays are JY (HLA type: A*0201, B7, Cw7, DR4, DRw6, DPw2) and EKR (HLA type: A3, B7, DR7, DQw2). The B-LCL used to confirm specific binding of reference peptides are B109, BRM, D100, D110, K97, ML, NL, P98, S59 and S99. The HLA type of these cell lines is given in fig. 1.

15

Peptides

Fluorescein (FL)-labeled reference peptides were synthesized as Cys-derivative. Labeling was performed with 4-(iodoacetamido)fluorescein (Fluka Chemie AG, Buchs, Switzerland) at pH 7.5 (Na-phosphate in water/acetonitrile 1:1). The labeled peptides were desalted over Sephadex G-10 and further purified by C18 RP-HPLC. Labeled peptides were characterized by MALDI-MS (Lasermat, Finnigan, UK). The reference peptide used for HLA-A*0301 binding was KVFPC(FL)ALINK ($MH^+_{calc}=1521.8$, $MH^+_{meas}=1521.4$), the reference peptide for HLA-A*0201 was FLPSDC(FL)FPSV ($MH^+_{calc}=1500.6$, $MH^+_{meas}=1500.1$).

25

The reference peptides used for binding to HLA-A*0301 or HLA-A*0201 were published by Sette et al. (14). In both peptides these investigators introduced a tyrosine which they used to tag a radioactive label to the peptide. We have substituted this tyrosine for a cysteine. The cysteine allowed the conjugation of 4-(iodoacetamido)fluorescein.

30

The polymerase amino-acid sequences of 14 different full length sequenced HIV-1 virus strains: LAI, MN, NL43, OYI, SF2, RF, MAL, D31, CAM1, HAN, ELI, NDK, JRCSF and JRFL (15) were screened for possible HLA-A*0301 restricted CTL epitopes

35

SUBSTITUTE SHEET (RULE 26)

using a scoring system (1). The HLA-A*0301 motif used was based on the studies of Kubo et al. (16) and Engelhard (17). At the anchor at position 2 a L, I, V or M and at the C-terminal anchor a K, R or Y was preferred. Peptides were
5 synthesized that contained the mentioned residues at both anchor positions and were completely conserved among all 14 HIV-1 strains.

Peptides were synthesized by solid-phase strategies on an automated multiple peptide synthesizer (Abimed AMS 422,
10 Langenfeld, Germany) using Fmoc-chemistry. Peptides were analyzed by reverse phase HPLC, dissolved in 20 µl dimethyl sulfoxide (DMSO), diluted in 0.9% NaCl to a peptide concentration of 5 mg/ml and stored at -20°C before usage.

15 *Mild-acid treatment of B-LCL*

Mild-acid treatment of HLA-A2 or HLA-A3 on B-LCL was performed according to Bremers modification (18) of the procedure of Storkus et al. (19). Briefly, cells were washed twice with PBS and then put to rest on ice for 5 minutes. The
20 cells were then treated 90 seconds with ice-cold citric-acid- Na_2HPO_4 buffer (mixture of an equal volume of 0.263 M citric acid and 0.123 M Na_2HPO_4) (20). For HLA-A3 the buffer was adjusted to pH=2.9 and to pH=3.2 for HLA-A2, these pH differences are essential for optimal elution of bound
25 peptides and reconstitution of the MHC class I molecule with the exogenous added peptide (18). Immediately thereafter the eluted cells were buffered with cold ISCOVE's modified Dulbecco's medium (IMDM), washed with IMDM and resuspended at 700.000 cells/ml in IMDM + 1,5 U μ g/ml β 2m (Sigma, St. Louis,
30 USA).

Peptide competition assay

For competition assays, 25 µl FL-labeled reference peptide (end conc:150 nM in PBS) was incubated with 25 µl competitor peptide (different end concentrations in PBS) in a 96-well U-bottom plate (Costar, Cambridge, Massachusetts, USA). 100 µl of the mild-acid treated B-LCL (A2:JY, A3:EKR) was added to these wells.

The mixture was incubated for 3 or 24 hr at 4°C or 26°C, washed twice with PBS containing 1% BSA (PBA1%), resuspended in PBA1% containing 0.5% paraformaldehyde and analyzed at a FACScan (Becton-Dickinson, Etten-Leur, the Netherlands).

The mean-fluorescence (MF) value obtained in the experiment without competitor peptide was regarded as maximal binding and equated to 0% inhibition, the MF obtained from the experiment without reference peptide was equated to 100% inhibition.

% inhibition of binding was calculated using the following formula:

$$(1 - \frac{\text{MF 150nM reference \& competitor peptide} - \text{MF no reference peptide}}{\text{MF 150nM reference} - \text{MF no reference peptide}}) \times 100\%$$

In experiments where no competitor peptide was added the fluorescence index (FI) was calculated to indicate how much fluorescence above the background (no reference peptide) was measured. The $FI = \frac{\text{MF sample} - \text{MF background}}{\text{MF background}}$.

To block protein synthesis in B-LCL a final concentration of 100 µM emetine (Sigma, St Louis, USA) was used, as shown previously (20).

Results

Sensitivity and specificity of FL-labeled reference peptides binding to HLA class I

The reference peptides binding to HLA-A*0201 and HLA-A*0301 were described and used in a molecular binding assay by Sette et al. (14) In both peptides a tyrosine was used to

SUBSTITUTE SHEET (RULE 26)

tag a radioactive label to the peptide. We substituted this tyrosine with cysteine, to which 4-(iodoacetamido)fluorescein was conjugated.

The amount of fluorescent peptide needed for the competition assay was established. For this purpose a peptide titration was performed. After incubation of three hours at 26°C the mean fluorescence (MF) was measured. At concentrations from 2 nM to 100 nM a sharp increase in MF was found for the HLA-A*0201 reference peptide and from 2 nM to 150 nM for the HLA-A*0301 reference peptide (data not shown). Mild-acid treatment of the B-cells before incubation with FL-labeled reference peptide resulted in a higher fluorescence maximum and also sharper increase of the MF at low peptide concentrations (fig. 7).

In order to investigate if aspecific peptide-binding to cell components, including other HLA class I alleles, at the surface of the cell line used occurred, 10 different B-LCL cell lines were incubated with 0 or 150 nM of FL-labeled reference (either HLA-A*0201 or HLA-A*0301) peptide. The FI for each cell line was calculated and the FIs obtained for reference cell lines JY (binding of peptide to HLA-A*0201) and EKR (binding of peptide to HLA-A*0301) were equated to 100% binding. To relate the binding of FL-labeled reference peptide to the 10 different cell lines with the binding of the FL-labeled reference peptide to JY or EKR, the relative peptide-binding percentages were determined. The relative peptide-binding percentages of the FL-labeled reference peptides to each cell line were calculated as: $(FI \text{ cell line} / FI \text{ reference cell line}) \times 100\%$. For both FL-labeled reference peptides the non-specific binding to other cell components, of the cell lines used in the competition assay, never exceeded 20% (fig 6). Because the peptide binding motif of HLA-A*0301 is very similar to the binding motif of HLA-A11 (16), binding of the HLA-A*0301 FL-labeled reference peptide to B-LCL cell lines expressing this allele was also observed (fig 6). The cell line NL binds the HLA-A*0301 FL-labeled reference peptide. It expresses the HLA-A28 allele of which

SUBSTITUTE SHEET (RULE 26)

two subtypes, HLA-Aw6801 and HLA-Aw6803, share the peptide-binding motif with HLA-A*0301 [A. Sette, personal communication].

5 *Kinetics of peptide-binding to mild-acid treated HLA class I molecules*

To study the effect of peptide binding at different temperatures, EKR cells were eluted and incubated with FL-labeled peptide for different periods of time at 4°C, 10 26°C or 37°C, respectively. At 4°C the peptide binds initially rapidly and then increases steadily in time (fig. 7). Peptide-binding at 26°C is faster (fig. 7). The amount of peptide bound after 6 hours at 26°C did not differ from the amount of peptide bound at 4°C. Peptide binds fast at 37°C 15 but no increase of bound peptide is found when incubated longer (fig. 7). The lack of increase in bound peptide at 37°C is probably due to two phenomena. The HLA class I molecules, present on the surface of the cell to which no peptide was bound, desintegrate at this temperature (21). 20 Secondly, the dissociation of peptides is dramatically faster at 37°C compared to the dissociation of peptides when incubated at 4°C (22).

SUBSTITUTE SHEET (RULE 26)

Binding to mild-acid treated class I molecules is not dependent on de novo protein synthesis

To characterize the interaction of peptides with cell-associated mild-acid treated HLA molecules, peptide stripped
5 EKR cells were incubated with FL-labeled peptide for different periods of time at 4°C or 26°C. As shown in figure 7, the fluorescent labeling at 4°C of the cells steadily increases in time. The use of 100 µM protein synthesis
10 inhibitor emetine for 1 hour prior to elution decreased the amount of peptide bound at 26°C but not at 4°C (fig 7).

Thus, the binding of a peptide to mild-acid treated HLA class I molecules at 4°C was unaffected by the use of a protein synthesis-inhibiting drug. Since metabolic processes are reduced at 4°C, the binding of peptides to the eluted HLA
15 class I molecules is only dependent on the availability of the HLA class I molecules already present at the outer surface of the cell.

Competition assay

20 Plotting MF against the concentration of FL-labeled reference peptides resulted in a log-shaped curve. We chose 150 nM of FL-labeled reference peptide as standard concentration in all competition experiments. The use of 150
25 nM FL-labeled reference peptide resulted in a MF of about 4-5 times the background (not shown). The non-labeled reference peptide was titrated into 150 nM of FL-labeled reference peptide, the percentage inhibition was calculated and plotted against the concentration of the unlabeled peptide (fig 5).
30 In a 24 hour competition assay at 4°C the non-labeled HLA-A*0201 or HLA-A*0301 reference peptide needed about 3-5 times (respectively 0,4 µM and 0,7 µM) the concentration used of the FL-labeled reference peptide to inhibit binding of the FL-labeled peptide to 50% (IC₅₀) (Table 1).

To determine the optimal experimental conditions and to
35 validate the assay we tested peptides derived from HPV16 E6 and E7 proteins with known binding properties to HLA-A*0201 or HLA-A*0301 (6, 10) at different concentrations, for 3 or

SUBSTITUTE SHEET (RULE 26)

24 hours at 4°C or 26°C (Table 1). When the cells were incubated for 24 hours less peptide was needed (Table 1). The lowest amount of competitor peptide was needed when the cells were incubated for 24 hours at 4°C (Table 1). No difference was observed between an incubation time of 24 hours or 48 hours at 4°C (not shown). This implicates that the test is more sensitive when equilibrium is reached. Probably, due to a faster association of the FL-labeled reference peptide, more competitor peptide is needed to reach IC₅₀ in short incubations. Ranking the peptides to their IC₅₀ shows that when the cells are incubated at 4°C for 24 hours, their order is comparable to that found by Kast et al. (6) using the molecular binding assay (Table 1). All peptides that did not possess the described binding motif showed low binding affinity. Taken together these results and the results of peptide-binding to HLA class I molecules on emetine-treated cells, we conclude that the competition assay is best performed at 4°C with an incubation time of at least 24 hours.

20

Competition with known CTL epitopes

Five HLA-A*0201 restricted CTL epitopes, one HLA-A*0301 restricted CTL epitope and two HLA-A*0301 peptides, identified via peptide pool-sequencing, were used to determine the IC₅₀-values of high affinity binding peptides. The five peptides tested for binding to HLA-A*0201 all competed very well with an IC₅₀ ≤ 1.7 μM (Table 2). The known HLA-A*0301 restricted CTL epitope derived from HIV was tested. This peptide, derived from HIV-nef, bound with an IC₅₀ of 0.5 μM. The two peptides, which were identified via peptide pool sequencing bound with an IC₅₀ ≤ 15 μM (Table 2). We therefore conclude that peptides competing with an IC₅₀ ≤ 5 μM must be considered potential CTL epitopes.

*Binding of conserved HIV-1 pol sequences to HLA-A*0301*

Twenty peptides of 8-11 amino acids long were selected on the basis of the HLA-A*0301 binding motif and their

SUBSTITUTE SHEET (RULE 26)

conservation in the polymerase gene products of different HIV-1 strains. The peptides were tested in the competition assay for 24 hours at 4°C. Nine peptides were shown to bind to HLA-A*0301. Four peptides bind with intermediate-affinity and competed with an $IC_{50} \leq 5 \mu M$ (Table 3), the other five peptides (marked with an asterisk; *) bind with high affinity and competed with an $IC_{50} \leq 3.0 \mu M$. Considering the IC_{50} obtained with the known CTL epitopes, especially these five peptides may be candidate CTL epitopes.

Comments

For an extensive discussion of these results see (3). This example shows that this assay performs well with respect to peptides of known binding capacity to either HLA-A*0201 or HLA-A*0301. The kinetics of peptide binding in this assay were shown to be comparable to that in assays employing soluble HLA class I molecules. Furthermore, application of the assay in the search for potential HLA-A*0301 restricted CTL epitopes, derived from HIV-1 polymerase, resulted in the identification of five high-affinity binding peptides. The assay is easy to perform because there is no need to purify HLA class I molecules, or to transfect cells with HLA class I molecules and no radioactive label is used. Moreover, large panels of HLA-typed human B-cell lines are available, as tools for peptide-binding to a vast array of HLA molecules. Presently, the system is also used successfully for the identification of peptides that bind to HLA-A*0101 and HLA-B7.

SUBSTITUTE SHEET (RULE 26)

Legends to Figures Example 1*Figure 1 . Specificity of FL-labeled reference peptides.*

Reference cell line EKR (HLA-A*0301) was mild-acid treated at pH=2.9. The reference cell line JY (HLA-A*0201) was mild-acid treated at pH=3.2, and the 10 different other B-LCL lines were mild-acid treated at pH=2.9, when subjected to incubation with the HLA-A*0301 FL-labeled reference peptide, or at pH=3.2 when incubated with the HLA-A*0201 FL-labeled reference peptide. EKR cells are incubated with 150 nM of the HLA-A*0301 FL-labeled reference peptide (*open bars*), JY cells are incubated with 150 nM of the HLA-A*0201 FL-labeled reference peptide (*hatched bars*) and the 10 different other B-LCL lines were incubated with 150 nM of either the HLA-A*0301 (*open bars*) or HLA-A*0201 FL-labeled reference peptide (*hatched bars*), for 4 hr at 26°C. The fluorescence index (FI) was calculated for each cell line and the FI of FL-labeled reference peptide bound to EKR (for binding to HLA-A*0301) and the FI of FL-labeled reference peptide to JY (for binding to HLA-A*0201) was equated to 100% binding. By the formula: $(\text{FI cell line} / \text{FI reference cell line}) * 100\%$ the relative peptide-binding percentages of the 10 different B-LCL lines was calculated. The upper left side shows the full HLA-type of the reference cell lines together with the overlapping HLA-type of other cell lines. The lower left side shows all 10 B-LCL lines with their full HLA-type.

Figure 2 . Peptide binding on eluted vs not-eluted HLA class I molecules.

JY cells (*closed symbols*) and JY cells of which their HLA class I molecules were mild-acid treated (*open symbols*), were incubated with increasing amounts (nM) of the HLA-A*0201 FL-labeled peptide. Cells were incubated for 3 hours at 26°C, washed and mean-fluorescence (mF) was measured at a FACScan. The lines shown are the result of logarithmic regression analysis of the concentration of FL-labeled reference peptide versus the mF.

SUBSTITUTE SHEET (RULE 26)

Figure 3 . Kinetics of peptide binding to mild acid treated HLA class I molecules.

EKR cells were mild acid treated and incubated with 150 nM of HLA-A*0301 FL-labeled reference peptide for different periods of time at 4°C (triangles), 26°C (open squares) or 37°C (closed squares). At 10, 20, 40, 90, 180 and 360 minutes the binding of FL-labeled peptide was measured. Binding is given as the fluorescence index (FI). The lines shown for 4°C and 26°C are the result of respectively linear or logarithmic regression analysis.

Figure 4. Binding of FL-labeled peptide to protein synthesis inhibiting drug treated cells.

EKR cells were treated with 10^{-4} M emetine (open bars) or not (hatched bars), for 1 hour prior to mild-acid treatment (20). 150 nM of HLA-A*0301 FL-labeled reference peptide was added and binding was monitored at 1, 3 or 4.5 hours of incubation. Cells were incubated at 26°C or 4°C.

Figure 5. Competition of non-labeled reference peptide with FL-labeled reference peptide.

EKR cells (left) or JY cells (right) were incubated with 150 nM of FL-labeled reference peptide, kvfpC(FL)alink or flpsdC(FL)fpsv respectively, and increasing amounts (μ M) of non-labeled reference peptide. Inhibition of binding was calculated and showed in relation to the amount of non-labeled reference peptide used.

§4.2 An HLA class I peptide-binding assay that measures the stability of peptide-MHC complexes at the surface of intact human B cells.

The binding affinity of peptides to MHC molecules at equilibrium is the resultant of the continued association and dissociation of the tri-molecular complex of peptide, MHC class I molecule and β 2m. The dissociation rate of peptides bound to MHC class I, is neither influenced by the presence of competing peptides (23) nor by the concentration of the

competing peptides (24). On the other hand, the amount of free MHC peptide binding sites is influenced and limited by the dissociation rate of previously bound peptide (24). Thus a peptide with a low dissociation rate will, once bound, probably form a stable MHC-peptide complex in the ER, be transported to the cell-surface and persist there for a time sufficient to allow T-cell recognition.

In order to investigate the correlation between stability of the peptide-MHC complex and immunogenicity we have determined the dissociation rate of a group of MHC class I binding peptides. This assay measures the stability of peptide-MHC complexes at the surface of intact HLA-homozygous B-cells. Comparison of the correlation between immunogenicity and peptide binding affinity on one hand and between immunogenicity and the dissociation rate of peptide from MHC class I molecules on the other hand has shown that immunogenicity correlates better with the dissociation rate than with peptide binding affinity.

As this complex-stability assay makes use of intact human B cells, it shares the advantages described for the peptide binding affinity assay (see §4.1).

Example 2.

Immunogenicity of peptides bound to MHC class I MHC molecules correlates well with stability of the MHC-peptide complex.

Material and Methods

Cell lines

The EBV transformed B-cell line: JY (HLA type:A*0201, B7, Cw7, DR4, DRw6, DPw2) was cultured in complete culture medium consisting of RPMI 1640 Dutch modification (Gibco BRL, Paisley, Scotland) supplemented with 10% FCS, antibiotics (100 IU/ml penicillin (Brocades Pharma, Leiderdorp, The Netherlands) and 100 ug/ml kanamycin (Sigma, St. Louis, MO, USA)), and 20 μ M 2-ME (Merck, Darmstadt, Germany) at 37°C in humidified air containing 5% CO₂.

SUBSTITUTE SHEET (RULE 26)

Jurkat A*0201K^b cells are stable transfectants of the human T cell leukaemia line, Jurkat, which express the product of the HLA-A*0201K^b chimeric gene (25). They are cultured in complete culture medium in the presence of
5 200ug/ml G418 sulphate.

Peptides

Peptides were synthesized by solid-phase strategies on an automated multiple peptide synthesizer (Abimed AMS 422, Langenfeld, Germany) using Fmoc-chemistry. Peptides were
10 analyzed by reverse phase HPLC, dissolved in 20 µl DMSO, diluted in 0.9% NaCl to a peptide concentration of 5 mg/ml and stored at -20°C before usage.

Fluorescein (FL)-labeled peptides as used in the competition based HLA class I binding-assay were
15 synthesized, labeled and characterized as described earlier (3). The sequence of the reference peptide used for HLA-A*0201 was FLPSDYFPSV (14) wherein we substituted the tyrosine with a cysteine to tag a fluorescein group to the
20 peptide: FLPSDC(FL)FPSV (3).

Transgenic mice

HLA-A*0201K^b transgenic mice were kindly provided by Dr L. Sherman (Scripps Laboratories, San Diego, USA; through
25 animal distributor Harlan Sprague Dawley, Inc., Indianapolis, USA). Mice were held under clean conventional conditions. The transgenic mice express the product of the HLA-A*0201K^b chimeric gene in which the a3 domain of the heavy chain is replaced by the corresponding murine H-2 K^b domain while
30 leaving the HLA-A*0201 a1 and a2 domains unaffected (25). This allows the murine CD8 molecule on the murine CD8+ T cells to interact with the syngeneic a3 domain of the hybrid MHC class-I molecule.

SUBSTITUTE SHEET (RULE 26)

In vivo immunizations and murine T cell cultures

Groups of 3-6 HLA-A*0201K^b transgenic mice were injected subcutaneously in the base of the tail with 100ug peptide emulsified in IFA in the presence of 140ug of the H-2 I-A^b-restricted HBV core antigen-derived T helper epitope (128-140; sequence TPPAYRPPNAPIL) (26). After 11 days, mice were sacrificed and spleen cells (30×10^6 cells in 10 ml) were restimulated *in vitro* with syngeneic irradiated LPS-stimulated B cell lymphoblasts (ratio 3:1), and 1 ug/ml peptide in complete culture medium in T25 flasks (Falcon, New Jersey, USA). At day 6 of culture, the cytotoxicity of these bulks was tested in a standard 5 hour ⁵¹Chromium (⁵¹Cr) release assay.

⁵¹Cr Cytotoxicity assay

CTL activity was measured in a standard chromium release assay as described previously (27). Target cells were sensitized with 10 ug/ml peptide for 30' at 37°C. Target cells were added to various numbers of effector cells in a final volume of 100 µl of complete culture medium in 96-wells U-bottom microtiter plates. After 5 hours of incubation at 37°C, supernatants were harvested. The mean percentage specific lysis of triplicate wells was calculated as follows:
% specific lysis = ((experimental release-spontaneous release) / (maximal release-spontaneous release)) x 100

Percentage specific lysis is expressed in LU30%/10⁶ cells, in which 1 LU30% corresponds to the number of effector cells required to induce 30% ⁵¹Cr release from 2000 Jurkat A*0201/K^b target cells during a 5-h assay.

Peptide 'stripping' by mild-acid treatment and competition based HLA class I peptide-binding assay

See Example 1

Measurement of MHC-peptide complex stability at 37°C

JY cells at a concentration of 1-2 million cells/ml were incubated with 10⁻⁴M emetine (Sigma, St. Louis, USA) for 1

SUBSTITUTE SHEET (RULE 26)

hour at 37°C to stop protein synthesis and thus the emergence of *de novo* synthesized class I molecules at the cell-surface (20). Cells were washed twice with PBS and peptide-stripped (see above). One million cells were added to 200ug peptide in 1 ml and incubated for 1 hour at room temperature. Cells were washed twice with ice-cold IMDM and resuspended in 1 ml IMDM. Subsequently, the cells were incubated for 0, 2, 4 and 6 hours at 37°C and thereafter stained with BB7.2, an HLA-A2 conformation specific monoclonal antibody (28) and GaM/FITC. Thereafter the cells were fixed by resuspension in PBA1% containing 0.5% paraformaldehyde. Cells were analyzed by FACscan. The fluorescence index (FI) was calculated as $FI = (\text{mean fluorescence sample} - \text{mean fluorescence background}) / \text{mean fluorescence background (without peptide)}$. Samples were tested in duplo and the variation between both samples was always less than 10%.

The percentage of residual HLA-A2 molecules was calculated by equating for each peptide, the FI of $t=0$ to 100% and then use the formula: $\% \text{remaining} = (FI_{t=n} / FI_{t=0}) \times 100\%$. As the dissociation of peptides from MHC is a linear process, the stability of the peptide-MHC complexes was measured as the time required for 50% of the molecules to decay (DT50%). We've used $t=2$ hours at 37°C as starting point for the reason that from this time point only the DT50% are determined from peptides that are able to form stable peptide-MHC complexes.

Statistics

Using the Fisher's test for 2 by 2 tables (Fisher's exact 2-tailed test), the dissociation rate (DT50%) of peptides at 37°C was correlated to the immunogenicity of the peptides. Binding-affinity could not be correlated to immunogenicity using a Chi-square test due to the relatively small number of peptides. Therefore we compared high affinity binding peptides with low affinity binding peptides in order to establish the strongest correlation between affinity and immunogenicity using the Fisher's test for 2 by 2 tables.

SUBSTITUTE SHEET (RULE 26)

Results

*Stability of MHC class-I molecules complexed with HBV or HPV16 derived peptides of known binding affinity and immunogenicity in HLA-A*0201/K^b transgenic mice*

5 To study the relation between dissociation of peptides bound to MHC class-I molecules and their ability to induce a CTL response, we used 9 peptides derived from HBV polymerase (pol) and 8 peptides of HPV16 of which the relative binding affinity and immunogenicity in HLA-A*0201/K^b transgenic mice
10 was reported previously (6, 10, 29). To show that all 17 peptides indeed bound to HLA-A*0201 we tested their affinity in a previously described competition based HLA-class I binding-assay (3). HBVpol-635, HPV16E7-11 and HPV16E7-86 bound with relatively high affinity (< 5 μ M). Fourteen
15 peptides bound with intermediate (between 5 and 15 μ M) or low affinity (> 15 μ M; Table I). Peptide binding affinities measured and classification of the peptide binding affinity into high, intermediate and low are comparable to the affinities and classifications of Sette et al. (10) and Kast
20 et al. (6).

Subsequently with the use of a conformation specific anti-HLA-A2 antibody, the amount of residual HLA-A*0201 peptide complexes was monitored in time. The loss of peptide-stabilized HLA-A*0201 molecules at the cell-surface
25 represents the dissociation of the peptide from the class-I molecule to which the peptide is bound. The stability is then presented by the time required for 50% of the molecules to decay (DT50%). All three high affinity binding peptides and three of the intermediate affinity binding peptides, HBVpol-
30 996, HBVpol-1076 and HPV16E7-82 showed a DT50% of more than 3 hours (Table I). The four other peptides of intermediate affinity, HBVpol-1344, HPV16E6-18, HPV16E6-52 and HPV16E7-7 showed a DT50% between 1 and 2 hours (Table I). The low
35 affinity binding peptides showed a DT50% of 1 hour or less. In Table II we show a comparison between the dissociation rate, binding affinity and immunogenicity of these peptides. All high affinity binding peptides form stable MHC-peptide

SUBSTITUTE SHEET (RULE 26)

complexes and are immunogenic, whereas the group of peptides of intermediate affinity contains either peptides that are immunogenic and form stable MHC-peptide complexes or are non-immunogenic and do not form stable MHC-peptide complexes as shown by their high dissociation rates (Table II).

Stability of MHC class-I molecules complexed with known human CTL epitopes

Seventeen HLA-A*0201 binding peptides earlier reported to be immunogenic (e.g. found as CTL epitope or capable of inducing a primary response) (6, 12, 27, 30-40) were tested for their binding affinity to HLA-A*0201. Eight peptides bound with high affinity, 7 peptides bound with intermediate affinity and 2 peptides bound with low affinity (Table III). The dissociation rates were determined and virtually all peptides showed a DT50% > 4 hours, except for the peptides HPV11E7-4 and HIV-1pol-267. The HPV11E7-4 and HIV-1pol-267 CTL epitopes, both found by primary CTL induction using synthetic peptide or cells expressing extremely high amounts of antigen, dissociated faster (DT50% > 2 hours ; Table III). Interestingly, the sequence of the HCV1core-131 peptide [ADLMGYIPLV] does not correspond precisely to the HLA-A*0201 motif. The HCVcore-132 peptide which lacks the N-terminal alanine [DLMGYIPLV] fits better to the HLA-A*0201 motif. This is also reflected in the higher affinity of this shorter peptide (IC₅₀=5.0 µM) but the peptide dissociates dramatically faster (Fig 1.) than the HCVcore-131 peptide.

Immunogenicity is correlated with the dissociation rate

A significant correlation exists between the immunogenicity of a peptide and the dissociation rate. Of the investigated known HLA-A*0201-restricted immunogenic peptides, 21 out of 23 showed a DT50% > 3 hours, while none of the 11 non-immunogenic peptides showed a DT50% > 3 hours (p=0.0000003, Table IV). This correlation is closer than that between peptide binding affinity and immunogenicity (p=0.0005, Table IV) and confirms the trend visible in

SUBSTITUTE SHEET (RULE 26)

Table II. When the correlation between immunogenicity and dissociation rate was investigated for peptides binding with intermediate or low affinity, this was still better correlated ($p=0.00007$, Table V) to immunogenicity than
5 affinity ($p=0.04$). This implies that peptides that are processed, transported to the endoplasmic reticulum and are able to form stable MHC-peptide complexes are likely to be CTL epitopes.

10 *Immunogenicity in HLA-A*0201/K^b transgenic mice of HIV-1 derived peptides with known affinity and dissociation rate*
To assess the *in vivo* immunogenicity of peptides of which the binding affinity and the dissociation rate was measured, HLA-A*0201/K^b transgenic mice were vaccinated with
15 two control peptides (HPV16E7-86 and HBVcore-18; FLPSDDFPSV) and four HIV-1 derived peptides (Table VI). The derivation of these transgenic mice (25) and their use to analyze *in vivo* immunogenicity have been described previously (10, 29). The HIV-1pol-468; (ILKEPVHGV) is a CTL epitope and binds with
20 intermediate affinity. The HIV-1pol-267; (VLDVGDAYFSV) peptide was found to be immunogenic in a human primary CTL induction after repetitive stimulations with relatively high doses of peptide (27). To test the predictive value of the *in vitro* measured MHC-peptide complex stability we determined the
25 binding-affinity and dissociation rate of the two other HIV-1pol peptides (HIV-1pol-343: YMDDLIVGSDL and HIV-1pol-576: LLWKGEHAV) (Table VI). Both peptides were detected when the highly conserved regions of HIV-1pol were screened for amino acid sequences that contained two anchors for binding to HLA-
30 A*0201, as described previously (27). We vaccinated groups of mice with all the peptides. Bulk CTL derived from mice vaccinated with the control peptides specifically lysed peptide-sensitized Jurkat A*0201/K^b cells (Fig. 2; Table VI). As expected, all peptides with a low dissociation rate
35 mounted a CTL response (Fig. 2 ; Table VI), whereas the two peptides with high relative dissociation rates did not induce a CTL response (Fig. 2; Table VI). Thus, the immunogenicity

SUBSTITUTE SHEET (RULE 26)

of these peptides was perfectly predicted by their dissociation rates.

Comments

5 An extensive discussion of these results with respect to
HIV-specific T cell immunity will be reported elsewhere (Van
der Burg et al., in preparation). This example shows that the
measurement of MHC-peptide complex stability is highly
valuable in identifying potential T cell epitopes. Newly
10 defined immunogenic peptides formed relatively stable MHC-
peptide complexes as shown by their low dissociation rates,
whereas non-immunogenic peptides displayed high dissociation
rates. In addition, virtually all previously described HLA-
A*0201 restricted T cell epitopes showed low dissociation
15 rates. Furthermore, we show that the immunogenicity of HIV-1
derived peptides can be predicted more accurately by their
dissociation rate than by the MHC class I binding affinity.
We find a closer correlation between the dissociation rate of
a peptide and immunogenicity ($p=0.0000003$) than between
20 binding affinity and immunogenicity ($p=0.0005$). The better
correlation is gained in the group of peptides that bind with
intermediate or low affinity. In conclusion, selection of
peptides based on affinity and their dissociation rate leads
to a more precise identification of candidate CTL epitopes
25 than selection based on affinity alone.

Note that this assay requires HLA-type specific MABs
that can discriminate between empty and peptide-loaded
molecules. Although such Abs are currently available for HLA-
A*0201 and -A*0301, additional Abs need to be identified or
30 isolated for defining the stability of peptide-MHC complexes
in the context of other HLA class I molecules. Approaches to
isolate such Abs include:

- * Screening of available Abs (ATCC, other laboratories)
for desired characteristics
- 35 * Selection of appropriate Abs against a human B cell line
expression the relevant HLA-molecule from a semi-synthetic
phage antibody display library (in collaboration with Dr. T.

SUBSTITUTE SHEET (RULE 26)

Lochtenberg, University Hospital Utrecht, The Netherlands;
(41)).

- * Generation of monoclonal Abs, or selection of phage
antibodies against purified, peptide-loaded MHC molecules
5 (6).

Legends to Figures Example 2

Figure 6. Binding affinity and dissociation rate of the
HCVIcore-131 peptide and the shorter variant without the
10 N-terminal alanine.

The binding affinity (left) and the dissociation rate
(right) of the HLA-A*0201 restricted CTL epitope HCVIcore-131
[closed symbols; ADLMGYIPLV] (31) and shorter variant [open
symbols; DLMGYIPLV], which corresponds more precisely to the
15 HLA-A*0201 motif, was tested (see material & methods). The
mean inhibition of the reference peptide at each
concentration of competitor peptide, obtained in two
independent experiments, is shown at the left. The right
figure shows the percentage of residual peptide-MHC molecules
20 for both peptides at each time-point (mean of two independent
experiments). The percentage of molecules present at t=2
hours was set to 100%. The lines are the result of linear
regression analysis.

25 Figure 7. Peptide-specific cytotoxicity induced by
vaccination of HLA-A*0201K^b transgenic mice.

A representative experiment in which HLA-A*0201K^b
transgenic mice were vaccinated with indicated peptide
displaying a low dissociation rate (A,B,E) or high
30 dissociation rate (C,D) in combination with an HBV core-
encoded T helper epitope in IFA (see material and methods).
Bulk CTL cultures derived from spleen cell of these mice were
tested for peptide specificity in cytotoxicity assays on
Jurkat A*0201K^b target cells pulsed with (open symbols) or
35 without (closed symbols) specific peptide. Shown is the mean
specific lysis of bulk CTL from 3-6 animals with indicated

SUBSTITUTE SHEET (RULE 26)

standard deviation. Specific lysis is depicted at E/T ratio varying from 1.5 to 100.

Example 3

- 5 Identification of melanoma associated immunogenic peptides using an assay that measures stability of the MHC-peptide complex.

Materials and methods

- 10 Most procedures have been described in Examples 1 and 2. Induction of CTL by stimulating human T lymphocytes with peptide-loaded dendritic cells (DC) was performed as follows: Monocyte-enriched Human Peripheral Blood Monocyte (PBMC) fractions were isolated by plastic adherence of total PBMC
15 from HLA-A*0201-subtyped healthy donors. Adherent cells were cultured for 5-7 days with RPMI/L-glutamine/antibiotics/10% FCS or 10% human serum (HS), and 500 U/ml rHuIL-4, and 800 U/ml rHuGM-CSF. Culture medium with cytokines was replenished every other day. Cultures were treated for 24 h with 50 U/ml
20 rHuIL-1a and 200 U/ml γ -IFN, and pulsed with 50 μ g/ml peptide in RPMI/L-glutamine/antibiotics/1% FCS for 4 h. Peptide-pulsed stimulators were irradiated (2500 Rads) and washed twice. In each well of a 24-well plate 1 ml of RPMI/L-glutamine/antibiotics/5% HS was dispensed containing 1-
25 2×10^4 /ml stimulator cells.

- Autologous responder cells were enriched for (CD8+) T-cells by adherence to plastic dishes, followed by depletion of CD4+ cells using Dynabeads (Dynal, Oslo, Norway). Total PBMC responders were mixed with the CD8-enriched non-adherent
30 cells, to bring the final responder population to approximately 10% CD4+ T cells. Responders were mixed with stimulators in a 1:10 to 1:20 ratio, to a total of 2×10^6 responders per well. rHuIL-7 was added to 5 ng/ml. Medium + rHuIL-7 was replenished after 7 days. At day 12, responders
35 were restimulated with autologous peptide-pulsed adherent PBMC (as described previously: (42)). rHuIL-2 was added to a

SUBSTITUTE SHEET (RULE 26)

final concentration of 120 IU/ml. Similarly, CTL cultures were restimulated weekly. CTL cultures were subcloned in U-bottom 96-well plates by limiting dilution, using the HLA-A*0201+, MelanA/MART-1 expressing FM3 Melanoma cell line (5000/well; (43)), and a mixture of allogenic PBMC from six donors (100,000/well) and three HLA-A*0201+ B-LCL (5000/well), in RPMI/L-glutamine/antibiotics/5% HS + 120 IU/ml rHuIL-2. Clones were restimulated weekly.

10 Results

The melanoma antigen Melan-A/MART-1 was screened for the presence of potential HLA-A*0201-binding CTL epitopes using three peptide binding assays: the T2-binding assay (2), a binding assay that uses HLA-A*0201-molecules on intact human B cells (see Example 1), and an assay that measures the stability of the MHC-peptide complexes (see Example 2). Comparison of the binding-data (see Table IX) shows that the nonamer peptide AAGIGILTV, which represents a previously described immunodominant peptide-epitope presented by HLA-A*0201-positive melanoma cells (44), binds poorly to T2 cells and only shows modest binding to HLA-A*0201 on intact human B cells. The 10-mer variant of this peptide (EAAGIGILTV), however, displays considerable binding to HLA-A*0201 in both binding assays. Paradoxically, comparison of these two peptides with respect to the stability of peptide-MHC complexes shows that the 9-mer peptide, when bound to HLA-A*0201, forms stable peptide-MHC complexes, whereas complexes with the 10-mer peptide are unstable.

Peptide-specific CTL immunity was raised in vitro by stimulating peripheral blood lymphocytes of HLA-A*0201-positive healthy donors with autologous dendritic cells that were loaded with either of the two peptides. The reactivity of the resulting CTL was tested against T2 cells loaded with the relevant peptides as well as to HLA-A*0201- and MART-1-positive human melanoma cells. These experiments clearly demonstrated that tumor-specific CTL activity that reacted against both peptide-loaded T2 cells and melanoma cells was

SUBSTITUTE SHEET (RULE 26)

only obtained after stimulation of the donor lymphocytes with the 9-mer peptide AAGIGILTV (these experiments will be described elsewhere; Van den Elsas et al., manuscript in preparation). These data clearly demonstrate that

5 immunogenicity of a peptide epitope correlates strongly with the stability of the corresponding peptide MHC complex, whereas MHC-binding of a peptide as measured on T2 cells or intact B cells does not ensure that this peptide (i) will form stable MHC-peptide complexes and (ii) is immunogenic
10 found to show strong and stable binding to HLA-A*0201 in all three assays (see Table IX). Also against these two peptides CTL reacting against both peptide-loaded T2 cells and HLA-A*0201-/MART-1 positive melanoma cells could be raised (Van den Elsas et al., manuscript in prep.).

15 Taken together these results show that selection of immunogenic peptides based on stability of the MHC-peptide complex is a valuable tool in the identification of tumor-associated T cell epitopes.

20 §4.3 Identification of immunogenic peptides

The present invention provides an novel technique for identifying MHC-binding peptides that can serve as a target for an immunotherapeutical T cell response. This method will be applied in conjunction with other selection steps (see §1)
25 to screen the primary sequence of proteins that are expressed by for instance tumors for peptides that are likely to be processed and presented by tumor cells and that will constitute an immunogenic target for the T cell immune system.

30 Peptide-epitopes derived from the following antigens are included in our studies:

- * E6-protein of human papilloma virus type 16 and 18 (HPV16, HPV18)
- * E7-protein of human papilloma virus type 16 and 18
35 (HPV16, HPV18)
- * Gag, Pol and Env-proteins of human immunodeficiency virus (HIV)

SUBSTITUTE SHEET (RULE 26)

- * MAGE-2 human melanoma antigen
- * Tyrosinase human melanoma antigen
- * Melan-A/MART-1 melanoma antigen
- * p21Ras human onco-protein
- 5 * p53 human onco-protein
- * human carcino-embryonic antigen (CEA)
- * human epithelial cell adhesion molecule (EpCAM)
- * CD19 human B cell-specific protein
- * CD20 human B cell-specific protein
- 10 * CD44 cell surface glycoprotein
- * The immunoglobulin (Ig) variable domains of the Ig heavy and light chains expressed by B cell lymphomas

The sequences of the proteins mentioned above are screened
 15 for peptides that are likely to represent immunogenic T cell epitopes in the context of the following HLA class I molecules:

- * HLA-A*0101
- * HLA-A*0201
- 20 * HLA-A*0301
- * HLA-A*1101
- * HLA-A*2401
- * HLA-B7

25 § 4.4 List of peptides screened in a stability assay because they have been through the preselection procedures.

As illustrated in § 4.3 Examples 2 and 3, selection of immunogenic peptides is greatly improved in accuracy when
 30 peptides are screened not only for binding to the MHC molecules concerned, but also for the stability of the resulting peptide-MHC complexes. In previous publications we have described multiple potential immunogenic peptides derived from various (e.g. tumor-)antigens. These peptides
 35 were selected on the basis of a two-step procedure, consisting of (i) computer-prediction and (ii) binding assays that do not take into account the stability of peptide-MHC

SUBSTITUTE SHEET (RULE 26)

complexes. The person skilled in the art can now apply, and thereby further validate, our novel assay for measuring peptide-MHC complex stability with respect to these peptides. A list of these peptides is provided in Tables X - XX.

5

§ 4.5 Vaccination with recombinant adenoviruses harbouring several defined T cell epitopes in string-of-bead constructs.

T cell-mediated immunity to viruses or tumors can be induced in two ways: passive, by transfer of virus- or tumor specific T cells, or active, by exposure to antigen. In the latter case, antigen can be given to the host in many different forms, ranging from whole attenuated viruses or tumor cells to isolated proteins. In virtually all these cases the vaccines are not rationally designed in the sense that the minimal essential T cell epitopes are known. Therefore, immunization in these cases may not always lead to the desired effect. For example, immunization with attenuated viruses, like vaccinia, may induce unwanted side-effects or result in T cell immunity to epitopes that are subjected to antigenic variation by the wild-type virus. Likewise, immunization with a single protein can be ineffective, because it may induce only T cell-responsiveness to the immunodominant T cell epitopes, without inducing T cell-responses to other, subdominant T cell epitopes, or it may not contain sufficient CTL epitopes to cover the whole target population. In part, these disadvantages can be overcome by exploiting other vaccination strategies.

Vaccination strategies using recombinant viruses expressing the antigens of choice are currently under development. In the case of the development of anti-tumor vaccines, several tumor-associated antigens, like MART1 and gp100 are good candidates for the incorporation into a recombinant viral vector. However, the delivery of whole genes encoding tumor-associated antigens by recombinant viral vectors as a way to evoke anti-tumor immunity might be unsafe when these tumor-associated antigens are involved in

SUBSTITUTE SHEET (RULE 26)

carcinogenesis. For example, viral vector vaccines for treatment and prevention of HPV16-positive cervical carcinoma are intrinsically hazardous if such vaccines contain the functional human papilloma virus type 16 (HPV16) E6 and E7 oncogenes. The same holds true when the viral vector encodes the oncoprotein HER2/neu, cyclin-dependent kinase 4, the aberrant fusion proteins BCR-ABL or mutated Ras and p53 proteins, because these genes are implicated in the development of cancer. Likewise, incorporation of the genes belonging to the family of tumor-associated antigens MAGE, GAGE or BAGE into viral vectors should be avoided, because their function has until now not been identified. However, by introducing only the sequences that encode T cell epitopes derived from such tumor-associated antigens into recombinant viral vectors it should be feasible to direct the immune response to those targets without introducing potential hazards as transformation of somatic, vector infected cells.

Recently, studies have been reported that describe the successful use of a recombinant vaccinia vaccine expressing several CTL epitopes in a string-of-bead fashion in mice (48), (49). These studies show the potency of the use of string-bead-vaccines for the induction of anti-viral and anti-tumor immunity. However, due to the potential risks associated with vaccinia and the decreasing or absent (in younger individuals) immunity to poxvirus due to the abolished vaccination programme with poxvirus, recombinant vaccinia vaccines cannot be used in humans. Moreover, in these studies the CTL epitopes were directly linked to each other, and did not contain spacer-sequences that direct efficient and accurate processing and presentation of the CTL epitopes. For these reasons, rAd harbouring several CTL epitopes in a string-of-bead fashion with proteolytic cleavage sites between the CTL epitopes leading to optimal processing and presentation of the incorporated CTL epitopes will induce stronger CTL responses without inducing harmful side-effects.

SUBSTITUTE SHEET (RULE 26)

Recombinant adenovirus, harbouring whole tumor-associated antigens, have been used to induce protective anti-tumor immunity (50-52). (53, 54), illustrating the possibility to use rAd for the induction of tumor-specific protective immunity.

By incorporation of minigenes containing multiple-T cell-epitopes and proteolytic cleavage sites in between these T cell epitopes into a rAd we now have developed a novel and innovative method for the induction of protective T cell responses against viruses and tumors.

Example 4.

An rAd expressing several defined CTL epitopes in a string-of-bead fashion induces protective anti-tumor immunity.

Materials and methods

Cell lines

Mouse embryo cells (MEC), Ad5E1 transformed MEC, Ad5E1 + ras transformed MEC, HPV16-transformed MEC, COS-7 cells were maintained in Iscove's modified Dulbecco's medium (Biocrom KG, seromed, Berlin, Germany) supplemented with 4% FCS (hyclone laboratories, Logan, Utah), penicillin, (110 IU/ml; Brocades Pharma, Leiderdorp, the Netherlands), and 2-mercaptoethanol (20 μ M) at 37°C in a 5% CO₂ atmosphere. CTL clones were cultured as described elsewhere (55, 56), (1057). The influenza matrix-specific HLA-A*0201-restricted CTL clone was grown on HLA-A*0201-positive EBV-transformed B cell lines irradiated with 30 Gy in RPMI. 911 cells were grown as described in (58).

Generation of rAd

Minigene 1 or minigene 2 (see Fig 8) were inserted into the shuttle vector pMad5. pMad5 (R. Hoeben, unpublished) was derived from pMLP10 (73) through the following cloning steps: (i) deletion of the SalI/BamHI-fragment, (ii) insertion of a

SUBSTITUTE SHEET (RULE 26)

polylinker sequence (ClaI, MluI, SnaBI, SpeI, AsuII, MunI) into the unique Hind III site, directly downstream of the Ad5 major late promoter (MLP) and Ad2 tripartite leader sequences, (iii) Insertion into the MunI site of a BglII/XhoI fragment of the Ad5 genome, which permits homologous recombination of the pMad5 sequences with sequences of pJM17 (see below). Insertion of minigenes 1 and 2 was performed in two steps. First pMad5 was cleaved with enzymes SpeI and MluI and the 5'ends were dephosphorylated. The annealed and phosphorylated double-stranded oligonucleotides 1a/b and 2a/b (see Table A) were ligated into this vector, which resulted in a small open reading frame consisting of a methionine, a spacer with the sequence NASYATS and the human c-myc sequence SEQKLISEEDLNN. The latter sequence corresponds to an epitope which can be recognized by the appropriate monoclonal antibody (74). As a result of the cloning strategy, the original SpeI and MluI sites of pMad5 were destroyed, whereas new SpeI and MluI sites were created between the Start codon and the c-myc epitope encoding sequence. In a second cloning step the CTL epitope encoding sequences were inserted into the cassette. The cassette vector was cleaved with enzymes SpeI and MluI and the annealed non-phosphorylated double-stranded oligonucleotides 3a/b and 4a/b were ligated into the open vector (minigene 1). Alternatively, the annealed non-phosphorylated double stranded oligonucleotides 5a/b and 4a/b were ligated into the open vector (minigene 2). Subsequently, the non-ligated oligonucleotides were removed from the ligation mixture by Sephacryl 400 column-purification. The eluted DNA was added to a ligation-reaction that contained the annealed and phosphorylated double-stranded oligonucleotides 6a/b and 7a/b (minigene 1), or phosphorylated double-stranded oligonucleotides 8a/b and 9a/b (minigene 2). As a result two pMad5-derived plasmids (pMad5-1, pMad5-2) were obtained coding for the recombinant proteins depicted in Fig 8. RAd were constructed by transfection of the Ad5E1-positive cell line 911 (58) with either plasmid pMad5-1 or pMad5-2 together with plasmid pJM17, which

SUBSTITUTE SHEET (RULE 26)

contains the sequence of the Ad5 mutant dl309 (59). 911 cells were co-transfected with 10 µg of linearized plasmid pMad5-1, respectively pMad5-2 and 10 µg of plasmid pJM17. The resulting rAd, which arose through homologous recombination between pMad5 and pJM17, were 3 times plaque-purified, and subsequently propagated in 911 cells, purified by double cesium-chloride density centrifugation and extensively dialysed. The presence of revertants was routinely checked by infection of HEP-G2 cells. The viral stocks were stored in aliquots with 10% glycerol at -80°C and titered by plaque assay using 911 cells.

Transfection of COS-7 cells.

Transient transfection in COS-7 cells was performed as described elsewhere (60). In short, 100 ng of Plasmids encoding Ad5E1, HPV16 E7, murine p53, or the influenza-matrix protein together with 100 ng of a plasmid encoding H-2D^b, H-2K^b or HLA-A*0201 were transfected by the DEAE-dextran-chloroquine method into 1x10⁴ COS-7 cells. The transfected COS cells were incubated in 100 µl Iscove's modified Dulbecco's medium containing 8% FCS for 48 h at 37°C, after which 1500-500 CTL in 25 µl Iscove's modified Dulbecco's medium containing 50 Cetus Units of recombinant Interleukin-2 (rIL-2, Cetus Corp., Emeryville, CA, USA) were added. After 24 h, the supernatant was collected and its tumor necrosis factor (TNF) content was determined by measuring its cytotoxic effect on WEHI-164 clone 13 cells as previously described (60).

Infection of MEC with rAd

B6 MEC were infected with rAd diluted in 1 ml Iscove's modified Dulbecco's medium containing 0.5% bovine serum albumine. After 30 minutes at room temperature Iscove's modified Dulbecco's medium containing 10% FCS was added. The multiplicity of infection (MOI) (for B6 MEC a moi of 50 was used) was chosen to give at least 80% of infected cell. This was determined by infection with Ad.RSVB-Gal carrying the

Escherichia coli LacZ gene, encoding β -galactosidase under control of the promotor from the rous sarcoma virus long terminal repeat, followed by X-gal staining 48 hours later.

5 Generation of CTL bulk cultures

5 x 10⁶ spleen cells per well, derived from B6 mice taken 2 weeks or more after the intra-peritoneal immunization with 1 x 10⁸ plaque forming units (PFU) of rAd or the replication-defective Ad5-mutant Ad5 ts 149 were co-cultured for 6 days with 10% irradiated (25GY) IFN- γ (10 units/ml) treated stimulator cells in 24-wells plates. Next, effector cells were harvested and dead cells were removed by density centrifugation on lympholyte M. These cells were used in a cell-mediated lymphocyte cytotoxicity assay.

15

Cell-mediated lymphocyte cytotoxicity.

Experimental procedures to measure cell-mediated cytotoxicity were performed in an Europium- (Eu³⁺) release assay as described elsewhere (56). In short, varying numbers of effector cells were added to 10³ Eur³⁺-labeled target cells in 0.15 ml of culture medium in 96-well U-bottomed plates. After a 4 hour incubation at 37°C, supernatants were collected and mixed with Enhancer solution® (Wallac, Turku, Finland). Measurement of the samples took place in a 1234 Delfia® fluorometer (Wallac). The mean percentage specific lysis of triplicate wells was calculated as follows:
% Specific lysis = [(cpm experimental release - cpm spontaneous release)/(cpm maximum release - cpm spontaneous release)] x 100.

30

Peptides.

Peptides were generated by solid phase strategies on a multiple peptide synthesizer (Abimed AMS 422) as described previously (61).

35

Tumor cell challenge.

SUBSTITUTE SHEET (RULE 26)

C57BL/6 mice were immunized intra-peritoneally with 1×10^8 plaque forming units (PFU) or rAd or the replication-defective Ad5-mutant Ad5 ts 149 in 0.25 ml PBS/BSA. Two weeks later the mice were sub-cutaneously challenged with 0.4×10^6 Ad5E1A + ras cells in 0.25 ml PBS. Tumor volumes were measured with a caliper. Animals were sacrificed when their tumors grew larger than 1000^3 mm to avoid unnecessary suffering.

10 RESULTS

Insertion of the coding sequences of several CTL epitopes into pMad5

Vaccination with recombinant viruses encoding intact oncoproteins is intrinsically hazardous, because it can lead to transformation of recombinant virus-infected cells. Therefore, we set out to assemble two minigenes encoding several different CTL epitopes, that were cloned behind the major-late promotor of the vector pMad5. Since we set out to study whether rAd expressing several CTL epitopes in a string-of-bead fashion can be used for vaccination purposes the CTL epitopes used for the construction of the minigene were selected on basis of the availability of CTL clones recognizing the CTL epitopes and/or tumor cells expressing the CTL epitopes. Based upon current knowledge of antigen processing and presentation the CTL epitopes were separated from each other by a spacer of three alanines. The incorporation of the proteolytic cleavage site of three alanines ensures that the encoded CTL epitopes are properly processed (62). The availability of CTL clones recognizing the minigene-encoded CTL epitope is important in order to determine whether the minigene is translated and whether the encoded CTL epitopes are presented in the context of the proper MHC class I-molecule. Likewise, the available murine tumor-models can be used as read-out in order to determine whether the constructed rAd are able, upon vaccination, to

induce protective respectively therapeutic CTL mediated anti-cancer immunity.

Based upon these considerations we generated two recombinant adenoviruses encoding two synthetic minigenes (Fig 8). The synthetic minigenes encoding the CTL epitopes depicted in figure 8 were cloned into plasmid pMad5 as described in the material and methods section. All CTL epitopes encoded by pMad5-1 and two of the four CTL epitopes encoded by pMad-2 were shown to be processed and presented to tumor-specific CTL as is shown in transient transfection experiments (Fig 9 and Fig 10). Processing and presentation of the HPV16 -derived HLA-A2-restricted CTL epitopes incorporated in pMad5-2 could not be tested, due to the fact that no CTL clones specific for these peptides are currently available. Nonetheless, our data indicate that these peptides are expressed and most likely processed, since the last (Ad5E1B-derived) CTL epitope in the construct is translated, processed and presented to Ad5E1B-specific CTL. We, therefore, conclude that all CTL epitopes encoded by pMad5-1 and pMad5-2 are translated, processed and presented to CTL clones.

Since introduction of the minigenes into cells leads to presentation of the desired CTL epitopes in the context of the appropriate MHC-restriction molecules, the plasmids pMad5-1 and pMad5-2 harbouring minigene 1 or 2 have been used to generate replication-defective rAd.

The CTL epitopes encoded by the constructed rAd are processed and presented to tumor-specific CTL.

In order to analyse whether the generated rAd are able, upon infection, to activate tumor-specific CTL clones, B6 MEC have been infected with the constructed rAd. These rAd-infected MEC were used as stimulator cells in a T cell activation assay, using TNF-production as read-out. For reasons of convenience, we focussed in these experiments on the H-2^b-encoded, virus-derived CTL epitopes. Upon infection with the rAd encoding minigene 1 (rAd-1), both the Ad5E1A-,

SUBSTITUTE SHEET (RULE 26)

HPV16 E7-, and the Ad5E1B-derived CTL epitopes are presented to the appropriate CTL, since these CTL were activated when incubated with B6 MEC infected with this virus, but not when incubated with B6MEC infected with a control rAd (Fig 11). By infection of MEC derived from p53 knock-out mice we were able to show that also the p53-derived CTL epitope was efficiently processed and presented to p53-specific CTL (data not shown). Likewise, the rAd encoding minigene 2 (rAd-2) is able to deliver the Ad5E1B-derived CTL epitope, since infection of B5 MEC with this virus leads to activation of Ad5E1B-specific CTL (Fig 11). Thus, the constructed rAd are able to deliver all pre-selected CTL epitopes to tumor-specific CTL.

5. Vaccination of B6 mice with rAd induces tumor-reactive CTL activity.

Since the rAd are able to deliver all three H-2-restricted viral CTL epitopes, we have analysed whether vaccination with these viruses induce CTL activity against these CTL epitopes. Indeed, bulk CTL cultures derived from B6 mice immunized with the rAd-1 display high CTL activity against the Ad5E1A-, HPV16 E7-, and the Ad5E1B-encoded CTL epitopes (Fig. 12 and Fig. 13). Moreover, these CTL bulk cultures also lyse tumor cells harbouring the relevant CTL epitopes, showing that the induced CTL display a strong anti-tumor activity. Similarly, vaccination of B6 mice with rAd-2 induced Ad5E1B-specific CTL activity that cross-reacted on Ad5E1B-expressing tumor cells (Fig. 12). Taken together, these data show that rAd harbouring synthetic minigenes encoding several CTL epitopes in a string-bead fashion are able to induce, upon vaccination, strong tumor-specific CTL responses against the CTL epitopes of choice.

Immunization with rAd-1 induces protective immunity against a challenge with Ad5E1A + ras transformed tumor cells.

The data described above show that immunization with rAd-1 or rAd-2 induce strong tumor-reactive CTL activity against all tested CTL epitopes. To test whether mice

SUBSTITUTE SHEET (RULE 26)

vaccinated with rAd are also protected against a lethal challenge with tumor cells, we challenged these mice with tumor cells transformed by the Ad5E1A-region and an activated ras oncogene (53). These tumor cells only express the Ad5E1A-
5 encoded CTL epitope, and it is therefore anticipated that rAd-1 only, but not rAd-2, is able to induce protective immunity against this tumor upon vaccination. Indeed, mice immunized with rAd-1, but not mice immunized with rAd-2 or PBS/BSA only, were protected against the outgrowth of Ad5E1A +
10 ras expressing tumor cells (Fig. 14). Moreover, the protection induced by vaccination with rAd-1 is better than that obtained by vaccination with irradiated tumor cells, showing that vaccination with rAd is superior compared to other vaccination regimes. Thus, vaccination with rAd, harbouring several
15 CTL epitopes, linked with a proteolytic cleavage site, is a powerful way to induce protective immunity directed against pre-selected T cell epitopes of choice.

Comments

20 This example shows that rAd encoding defined CTL epitopes in a string-of-bead fashion, in which the CTL epitopes are linked to each other by sequences that ensure efficient processing and presentation of the CTL epitopes are very potent in inducing protective CTL responses against tumors.
25 All CTL epitopes encoded by the rAd were processed and presented to tumor- and virus-specific CTL, illustrating that multiple CTL epitopes can be delivered to the host by a single vaccination, leading to strong and protective CTL responses. rAd are easy to manufacture, and do not cause side-effects
30 when used for vaccination, in contrast to other carriers as vaccinia. Therefore, this method of vaccination is very effective and safe and is currently being used to deliver other CTL epitopes described in this invention.

SUBSTITUTE SHEET (RULE 26)

Example 5.

Along the same way as described in Example 4, a vaccine will be prepared, in which the CTL epitopes are incorporated described in Tables X - XX. The vaccine is prepared with the following characteristics:

- a. the vaccine contains several T cell epitopes linked to each other by a spacer
- b. the spacers contain proteolytic cleavage sites
- 10 c. the T cell epitope containing construct is delivered by a recombinant adenovirus or is incorporated into the vaccine types described by point iii - vii on pages 2 and 3.

A vaccine for melanoma is prepared harbouring peptides mentioned in Table XI, a vaccine for colon carcinoma is prepared harbouring peptides mentioned in Tables XII and XX, a vaccine for cervical carcinoma is prepared harbouring peptides mentioned in Tables XIII - XVI, a vaccine for HIV is prepared harbouring the peptides mentioned in Table XIX. When appropriate, peptide T cell epitopes other than the ones listed in Tables X - XX are incorporated into these multi-epitope vaccines.

The T cell epitopes present in these vaccines are linked to each other by the following proteolytic cleavage sites (or part of these proteolytic cleavage sites):

AAA as described in (62)

QGW*FEG, WFE*GLF, FEG*LFN, FTT*LIS, TTL*IST, TLI*STI, FNK*SPW,
30 EGL*FNK, TTL*IST, TLI*STI, FNR*SPW as described in (63)

VSG*LEQ, SII*NFE, INF*EKL, LTE*WTS, IIN*FEK, GLE*QLE, EQL*ESI,

NFE*KLT, QLE*SII, EKL*TEW, VVR*FDK, STR*TQI, TQI*NKV,
35

KVV*RFD, VVR*FDK, VRF*DKL, RFD*KLP, DKL*PGF, FGD*SIE,

SUBSTITUTE SHEET (RULE 26)

VSG*LEQ, QLE*KVV, FDK*LTE, KLT*EWT as described in (64, 65)

LMY*DMY, SEK*RVV, KRV*WMS, DMY*PHF, TNL*GPS, LMY*DMY, as described in (66)

5

LYE*NKP as described in (67)

VNQ*HLC, SHL*VEA, LVE*ALY, EAL*YLV, LYL*VCG as described in (68)

10

VNQ*HLC, QHL*CGS, LVE*ALY, EAL*YLV, ALY*LVC, LYL*VCG,

YLV*CGE, LVC*GER, RGF*FYT, GFF*YTP, FFY*TPK, FYT*PKA,

15 YTP*KA, TPK*A as described in (69)

whereby * represent the site after which the proteasome complex cleaves.

20 RAd vaccines carrying multi-epitope constructs as described above are applied in the appropriate clinical setting as follows:

Dose:

25 between 10^5 and 10^{11} pfu

diluent: isotonic solution; 100 - 1000 μ l

Administration:

One to three times, at two-to four-week intervals

30

Possible sites:

Subcutaneous, intra-cutaneous, intra-peritoneal, intramuscular

Clinical evaluations:

35 Inhibition of tumor-growth, regression of existing tumors/metastases

SUBSTITUTE SHEET (RULE 26)

Immunological evaluation:

Measurement of T cell responses against relevant and control peptide T cell epitopes before and after vaccination.

SUBSTITUTE SHEET (RULE 26)

Legends to Figures Example 4

Fig. 8. Minigenes encoding several CTL epitopes, linked by a spacer of three alanines.

- 5 The first minigene (rAd-1) encodes an Ad5E1A₂₃₄₋₂₄₃-
encoded, H-2D^b-restricted CTL epitope (55), an HPV16E₇₄₉₋₅₉-
encoded, H-2D^b-restricted CTL epitope (70), a p⁵³₁₅₈₋₁₆₆-
encoded, H-2K^b-restricted CTL epitope (unpublished results), an
Ad5E1B₁₉₂₋₂₀₀-encoded, H-2D^b-restricted CTL epitope (56), and a
Myc-Tag.
- 10 The second minigene (rAd-2) encodes an HPV16 E₇₈₆₋₉₃-
encoded, HLA-A*0201-restricted CTL epitope (71), an Flu-
matrix₅₈₋₆₆, HLAA*0201-restricted CTL epitope (72), An HPV16
E₇₁₁₋₂₀-encoded, HLAA*0201-restricted CTL epitope (71), an
Ad5E1B₁₉₂₋₂₀₀-encoded, H-2D^b-restricted CTL epitope (56), and a
15 Myc-Tag.

- Fig. 9. Minigene I-encoded CTL epitopes are presented to
tumor-specific CTL clones. pMad5-1 was transfected, together
with a plasmid encoding the appropriate restriction element,
20 into COS-7 cells. After 48 hours, the transfected COS-7 cells
were tested for the expression of the CTL epitopes in their
ability to cause TNF-release by the relevant CTL. The presence
of TNF in the culture supernatant was measured by the
cytotoxic effect on WEHI-164 clone 13 cells.

- 25 All relevant CTL were activated by COS-7 cells
transfected with a plasmid encoding minigene 1 (but not an
irrelevant control plasmid) together with a plasmid encoding
the appropriate restriction molecule. Thus, minigene 1 is
30 translated into protein and the encoded CTL epitopes are
processed and presented in the context of the appropriate MHC-
molecule to tumor-specific CTL.

- Fig. 10. The Flu-derived and Ad5E1B-derived CTL epitopes
35 are presented to Flu-, respectively, Ad5E1B-specific CTL by
minigene 2. pMad5-2 was transfected, together with a plasmid
encoding the appropriate restriction element, into COS-7

SUBSTITUTE SHEET (RULE 26)

cells. After 48 hours, the transfected COS-7 cells were tested for the expression of the CTL epitopes in their ability to cause TNF-release by the relevant CTL. The presence of TNF in the culture supernatant was measured by the cytotoxic effect on WEHI-164 clone 13 cells. Relevant CTL were activated by COS-7 cells transfected with this plasmid (but not an irrelevant control plasmid) and a plasmid encoding the appropriate restriction molecule. Thus, minigene 2 is translated into protein and encoded CTL epitopes are processed and presented in the context of the appropriate MHC-molecule to specific CTL.

Fig. 11. CTL epitopes encoded by rAdV are processed, and presented to tumorspecific CTL. B6 MEC were left uninfected, or were infected with rAd-1 harbouring minigene 1, rAd-2, harbouring minigene 2 or the galactosidase gene (rAdV-LAC-Z) at an multiplicity of infection of 50. Two days later these cells were used in a TNF-production assay as described above. B6 MEC infected with the rAd-1 harbouring Ad5E1A-, HPV16 E7- and Ad5E1B-derived H-2D^b-restricted CTL epitopes are able to activate CTL clones. specific for these CTL epitopes, whereas B6 MEC infected with the rAd-2 harbouring an Ad5E1B-derived CTL only activate Ad5E1B-specific CTL. The CTL are not activated upon incubation with uninfected MEC or MEC infected with a control rAd.

Fig. 12. Vaccination with rAdV leads to induction of tumor-reactive CTL activity against the Ad5E1-encoded CTL epitopes. B6 mice were left non-immunized, were immunized with rAd-1, harbouring minigene 1, or were immunized with rAd-2, harbouring minigene 2. Two weeks later the spleens of these animals were taken and restimulated with Ad5E1-transformed tumor cells in order to propagate Ad5E1A- and Ad5E1B-specific CTL. Lytic activity of bulk CTL cultures was tested 6 days later on Ad5E1 MEC, B6 MEC loaded with the the Sendai-virus encoded control CTL epitope FAPGNYPAL, or the Ad5E1A-encoded CTL epitope SGPSNTPPE1, or the Ad5E1B-encoded CTL epitope

SUBSTITUTE SHEET (RULE 26)

VNIRNCCYI, or the HPV16 E7-encoded CTL epitope RAHYNIVTF. Mice immunized with rAd-1 recognize the Ad5E1A- and Ad5E1B-encoded CTL epitopes as well as tumor cells endogenously presenting the Ad5E1A- and the Ad5E1B-epitope. Mice immunized with rAd-2
5 recognize the Ad5E1B-epitope as well as tumor cells endogenously presenting the Ad5E1B-encoded CTL epitope, whereas non-immunized mice do not display reactivity against the target cells. % specific lysis at different effector to target cell ratio's is shown.

10

Fig. 13. Vaccination with rAdV leads to the induction tumor-reactive CTL activity directed against the HPV16 E7, H-2Db-restricted CTL epitope. B6 mice were left non-immunized, were immunized with rAd-1, harbouring minigene 1, or were
15 immunized with rAd-2, harbouring minigene 2. Two weeks later the spleens of these animals were taken and restimulated with HPV16-transformed tumor cells in order to propagate H-2Db, HPV16 E7-specific CTL. Lytic activity of bulk CTL cultures was tested 6 days later on HPV16 MEC, B6 MEC loaded with the the
20 Sendai-virus encoded control CTL epitope FAPGNYPAL, or the Ad5E1A-encoded CTL epitope SGPSNTPPE1, or the Ad5E1B-encoded CTL epitope VNIRNCCYI, or the HPV16 E7-encoded CTL epitope RAHYNIVTF. Mice immunized with rAd-1 recognize the HPV16 E7-encoded CTL epitopes as well as tumor cells endogenously
25 presenting the HPV16 E7-epitope. Non-immunized mice and mice immunized with rAd-2 do not display reactivity against HPV16 E7-peptide positive target cells. % specific lysis at different effector to target cell ratio's is shown.

30

Fig. 14. Vaccination with rAd-1 induces protective immunity against a lethal challenge with Ad5E1A-expressing tumor cells. B6 mice were immunized intraperitoneally with rAd-1, rAd-2, the Ad5-mutant (Ad5E1A-positive) Ad5tsl49, subcutaneously with 10 xO1 irradiated Ad5E1A + ras transformed
35 tumor cells, or were injected with PBS/BSA only. Two weeks later the mice received a subcutaneous challenge of 0.4×10^6 Ad5E1A + ras cells. Mice immunized with rAd-1 and Ad5tsl49 are

SUBSTITUTE SHEET (RULE 26)

protected against the outgrowth of Ad5E1A + ras cells, showing that immunization with rAd induces protective immunity against tumors.

SUBSTITUTE SHEET (RULE 26)

§5 References

1. D'Amaro, J., Houbiers, J.G.A., Drijfhout, J.W.D., Brandt, R.M.P., Melief, C.J.M. Kast, W.M. A computer program for
5 predicting possible cytotoxic T lymphocyte epitopes based on HLA class I peptide-binding motifs. *Human Imm.*, 43: 13-18, 1995.
2. Nijman, H.W., Houbiers, J.G.A., Vierboom, M.P.M., Van den burg, S.H., Drijfhout, J.W., D'Amaro, J., Kenemans, P.,
10 Melief, C.J.M. Kast, W.M. Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. *Eur. J. Immunol.*, 23: 1215-1219, 1993.
3. Van der Burg, S.H., Ras, E., Drijfhout, J.W.D., Benckhuijsen, W.E., Bremers, A.J.A., Melief, C.J.M. Kast, W.M.
15 An HLA class I peptide binding assay based on competition for binding to class I molecules on intact human B cells: identification of conserved HIV-1 polymerase peptides binding to HLA-A*0301. *Hum. Immunol.*, 44: 189-198, 1995.
4. Ossendorp, F., Eggers, M., Neisig, A., Ruppert, T.,
20 Groettrup, M., Sijts, A., Mengedé, E., Kloetzel, P.-M., Neefjes, J., Koszinowski, U. Melief, C.J.M. A single residue exchange within a viral CTL epitope alters proteasome-mediated degradation resulting in lack of antigen presentation. Submitted for publication., 1996.
- 25 5. Neisig, A., Roelse, J., Sijts, E.J.A.M., Ossendorp, F., Feltkamp, M.C.W., Kast, W.M., Melief, C.J.M. Neefjes, J.J. Major differences in TAP-dependent translocation of MHC class I presentable peptides and the effect of flanking sequences. *J. Immunol.*, 154: 1273-1279, 1995.
- 30 6. Kast, W.M., Brandt, R.M.P., Sidney, J., Drijfhout, J.W., Kubo, R.T., Grey, H.M., Melief, C.J.M. Sette, A. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. *J. Immunol.*, 152: 3904-3912, 1994.
- 35 7. Garboczi, D.N., Hung, D.T. Wiley, D.C. HLA-A2-peptide complexes: refolding and christallization of molecules

SUBSTITUTE SHEET (RULE 26)

- expressed in E.coli and complexed with single antigenic peptides. Proc.Natl.Acad.Sci.USA, 89: 3429-3433, 1992.
8. Parker, K.C., Silver, M.L. Wiley, D.C. An HLA-A2/B2-microglobulin/peptide complex assembled from subunits e
5 expressed separately in E.coli. Mol.Immunol., 29: 371-378, 1992.
9. Feltkamp, M.C.W., Vierboom, M.P.M., Toes, R.E.M., Ossendorp, F., Ter Schegget, J., Melief, C.J.M. Kast, W.M. Competition inhibition of cytotoxic T lymphocyte (CTL) lysis,
10 a ore sensitive method to identify candidate CTL epitopes that antibody-detected MHC class I stabilization. Immunol. Letters, in press: 1995.
10. Sette, A., Vitiello, A., Reheman, B., Fowler, P., Nayersina, R., Kast, W.M., Melief, C.J.M., Oseroff, C., Yuan,
15 L., Ruppert, J., Sidney, J., Del Guerco, M.F., Southwood, S., Kubo, R.T., Chesnut, R.W., Grey, H.M. F.V., C. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol., 153: 5586-5592, 1994.
- 20 11. Castelli, C., Storkus, W.J. Mauerer, B.M. J.Exp.Med., 181: 363-368, 1995.
12. Cox, A.L., Skipper, J., Chen, Y., Henderson, R.A., Darrow, T.L., Shabanowitz, J., Engelhard, V.H., Hunt, D.F. Slingluff, C.L. Identification of a peptide recognized by five melanoma-specific cytotoxic T cell lines. Science, 264: 716-719, 1994.
- 25 13. Nijman, H.W., Houbiers, J.G.A., Van der Burg, S.H., Vierboom, M.P.M., Kenemans, P., Kast, W.M. Melief, C.J.M. Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self-protein, influenza matrix:
30 relationship between MHC peptide binding affinity and immune responsiveness to peptides. J. Immunother., 14: 121-126, 1993.
14. Sette, A., Sidney, J., Del Guercio, M.F., Southwood, S., Ruppert, J., Grey, H.M. Kubo, R.T. Peptide binding to the most frequent HLA-A class I alleles measured by quantative
35 molecular binding assays. Mol. Immunol., 31: 813-822, 1994.

SUBSTITUTE SHEET (RULE 26)

15. Myers, G., Wain-Hobson, S., Korber, B., Smith, R.F. Pavlakis, G.N. in , Los Alamos National Laboratory, Los Alamos, 1993,
16. Kubo, R.T., Sette, A., Grey, H.M., Apella, E., Sakaguchi, K., Zhu, N.Z., Arnott, D., N., S., Shabanowith, J., Michel, H., Bodnar, W.M., Davis, T.A. Hunt, D.F. Definition of specific peptide motifs for four major HLA-A alleles. *J.Immunol.*, 152: 3913-3926, 1994.
17. Engelhard, V.H. Structure of peptides associated with MHC class I molecules. *Curr. Opin. Immunol.*, 6: 13-23, 1994.
18. Bremers, A.J.A., Van der Burg, S.H., Kuppen, P.J.K., Kast, W.M., Van de Velde, C.J.H. Melief, C.J.M. The use of Eppstein Barr virus-transformed B lymphocyte cell lines in a peptide-reconstitution assay: Identification of CEA-related HLA-A*0301-restricted potential cytotoxic T lymphocyte epitopes. *J.Immunother.*, 18: 77-85, 1995.
19. Storkus, W.J., Zeh III, H.J., Salter, H.D. Lotze, M.T. Identification of T cell epitopes: Rapid isolation of class I presented peptides from viable cells by mild acid elution. *J. Immunother.*, 14: 94-105, 1993.
20. Suguwara, S., Abo, T. Kumagai, K. A simple method to eliminate the antigenicity of surface class I MHC molecules from the membrane of viable cells by acid treatment at pH 3. *J. Immunol. Methods*, 100: 83-90, 1987.
21. Ljunggren, H.-G., Stam, N., J., Öhlen, C., Neefjes, J.J., Höglund, P., Meemels, M.-T., Bastin, J., Schumacher, T.N.M., Townsend, A., Kärre, K. Ploegh, H.L. Empty MHC class I molecules come out in the cold. *Nature*, 346: 476-480, 1990.
22. Cerundolo, V., Elliott, T., Elvin, J., Bastin, J., Rammensee, H.-G. Townsend, A. The binding affinity and dissociation of peptides for class I major histocompatibility complex molecules. *Eur. J. Immunol.*, 21: 2069-2075, 1991.
23. Neefjes, J.J., Diers, J. Ploegh, H.L. The effect of anchor residue modifications on the stability of major histocompatibility complex class I-peptide interactions. *Eur. J. Immunol.*, 23: 840-845, 1993.

SUBSTITUTE SHEET (RULE 26)

24. Ojcius, D.M., Abastado, J.-P., Casrouge, A., Mottez, E., Cabanie, L. Kourilsky, P. Dissociation of the peptide-MHC class I complex limits the binding rate of exogenous peptide. *J. Immunol.*, 151: 6020-6026, 1993.
- 5 25. Vitiello, A., Marchesini, D., Fruze, J., Sherman, L.A. Chesnut, R.W. Analysis of the HLA-restricted influenza-specific CTL response in transgenic mice carrying a chimeric human-mouse class I MHC. *J.Exp.Med.*, 173: 1007-1018, 1991.
- 10 26. Milich, D.R.J.L., Hughes, L.J., McLachlan, A., Thornton, G.B. Moriarty, A. Hepatitis B synthetic immunogen comprised of nucleocapsid T cell sites and envelop B protein. *Proc.Natl.Acad.Sci.USA*, 85: 1610-1615, 1988.
- 15 27. Van der Burg, S.H., Klein, M.R., Van de Velde, C.J.H., Kast, W.M., Miedema, F. Melief, C.J.M. Induction of primary human cytotoxic T lymphocyte response against a novel conserved epitope in a functional sequence of HIV-1 reverse transcriptase. *AIDS*, 9: 121-127, 1995.
- 20 28. Parham, P. Brodsky, F.M. Partial purification and some properties of BB7.2. A cytotoxic monoclonal antibody with specificity for HLA-A2 and a variant of HLA-A28. *Hum. Immunol.*, 3: 277-286, 1981.
- 25 29. Rensing, M.E., Sette, A., Brandt, R.M.P., Ruppert, J., Wentworth, P.A., Hartman, M., Oseroff, C., Grey, H.M., Melief, C.J.M. Kast, W.M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201-binding peptides. *J. Immunol.*, 154: 5934-5943, 1995.
- 30 30. Cerny, A., McHutchinson, J.G., Pasquinelli, C., Brown, M.E., Brothers, M.A., Grabscheid, B., Fowler, P., Houghton, M. Chisari, F.V. Cytotoxic T lymphocyte response to hepatitis B virus-derived peptides containing the HLA-A2.1 binding motif. *J.Clin.Invest.*, 95: 1995.
- 35 31. Nayersina, R., Fowler, P., Guihot, G., Missale, G., Cerny, A., Schlicht, H.J., Vitiello, A., Chesnut, R., Person, J.L., Redeker, A.G. Chisari, F.V. HLA-A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen

SUBSTITUTE SHEET (RULE 26)

- epitopes during hepatitis B virus infection. *J. Immunol.*, 150: 4659-4666, 1993.
32. Lee, S.P., Thomas, W.A., Murray, R.J., Khanim, F., Kaur, S., Tounq, L.S., Rowe, M., Kurilla, M. Rickinson, A.B. HLA
5 A2.1-restricted cytotoxic T cells recognizing a range of Epstein Barr virus isolates through a defined epitope in latent membrane protein. *J.Virol.*, 67: 7428-7439, 1993.
33. Utz, U., Koenig, S., Coligan, J.E. Biddison, W.E. Presentation of three different viral peptides, HTLV-1 TAX,
10 HCMV gB and influenza virus M1, is determined by common structural features of the HLA-A2.1 molecule. *J.Immunol.*, 149: 214-223, 1992.
34. Tarpey, I., Stacey, S., Hickling, J., Birley, H.D.L., Renton, A., McIndoe, A. Davies, D.H. Human cytotoxic T
15 lymphocytes stimulated by endogeneously processed HPV11 E7 recognize a peptide containing a HLA-A2 (HLA-A*0201) motif. *Immunology*, 81: 222-227, 1994.
35. Robbins, P.A., Lettice, L.A., Rota, P., Santos-Aguado, J., Rothbard, J., McMichael, A.J. Strominger, J.L. Comparison
20 between two peptide epitopes presented to cytotoxic T lymphocytes by HLA-A2. Evidence for discrete locations within HLA-A2. *J.Immunol.*, 143: 4098-4112, 1989.
36. Morrison, J., Elvin, J., Latron, F., Gotch, F., Moots, R., Strominger, J.L. McMichael, A. Identification of the
25 nonamer peptide from Influenza A matrix protein and the role of pockets of HLA-A2 in its recognition by cytotoxic T lymphocytes. *Eur. J. Immunol.*, 22: 903-..., 1992.
37. Johnson, R.P., Trocha, A., Yang, L., Mazzara, G.P., Panicali, D.L., Buchanan, T.M. Walker, B.D. HIV-1 gag-specific
30 cytotoxic T lymphocytes recognize multiple highly conserved epitopes. *J.Immunol.*, 147: 1512-1524, 1991.
38. Tsomides, T.J., Walker, B.D. Eisen, H.N. An optimal viral peptide recognized by CD8+ T cells binds very tightly to the restricting class I MHC protein on intact cells but not to the
35 purified class I protein. *Proc. Natl. Acad. Sci. USA*, 88: 11276-, 1993.

SUBSTITUTE SHEET (RULE 26)

39. Kawakami, Y., Eliyahu, S., Delgado, C.H., Robbins, P.F., Sagaguchi, K., Apella, E., Yanelli, J.R., Adema, G.J., Miki, T. Rosenberg, S.A. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with
5 in vivo tumor rejection. Proc.Natl.Acad.Sci.USA, 91: 6458-6464, 1994.
40. Wölfel, T., Van Pel, A., Brichard, V., Schneider, J., Seliger, B., Meyer-Zum Buschenfelde, K.H. Boon, T. Two tyrosinase nonapeptides recognized on HLA-A2 melanomas by
10 autologous cytolytic T lymphocytes. Eur.J.Immunol., 24: 759-769, 1994.
41. De Kruijf, J., Boel, E. Logtenberg, T. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed
15 CDR3 region. J. Mol. Biol., 248: 97-105, 1995.
42. Visseren, M.C.W., Van Elsas, A., Van der Voort, E.I.H., Rensing, M.E., Kast, W.M., Schrier, P.I. Melief, C.J.M. CTL specific for the tyrosinase autoantigen can be induced from healthy donor blood to lyse melanoma cells. J. Immunol., 154:
20 3991-3998, 1995.
43. Olsen, A.C., Fossum, B., Kirkin, A.F., Zeuthen, J. Gaudernack, G. Scand.J.Immunol., 41: 357-369, 1995.
44. Kawakami, Y., Eliyahu, S., Sakaguchi, K., Robbins, P.F., Rivoltini, L., Yanelli, J.R., Apella, E. Rosenberg, S.A.
25 J.Exp.Med., 180: 347-358, 1994.
45. Bednarek, M.A., Sauma, S.Y., Gammon, M.C., Porter, G., Tamhankar, S., Williamson, A.R. Zweerink, H.J. The minimum peptide epitope from the influenza virus matrix protein. Extra and intra-cellular loading of HLA-A2. J. Immunol., 147: 4047-
30 4053, 1991.
46. Kawakami, Y., Eliyahu, S., Delgado, C.H., Robbins, P.F., Rivoltini, L., Topalian, S.L., Miki, T. Rosenberg, S.A. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor.
35 Proc. Natl. Acad. Sci. USA, 91: 3515-3519, 1994.

SUBSTITUTE SHEET (RULE 26)

47. Cox, A.L., Skipper, J., Chen, Y., Henderson, R.A., Darrow, T.L., Schabanowith, J., Engelhard, V.H., Hunt, D.F., Slingluff, C.L. *Science*, 264: 716-722, 1993.

References

- 5 48. Whitton, J.L., Sheng, N., Oldstone, M.B.A. McKee, T.A. A "string-of-beads" vaccine, comprising linked minigenes confers protection from lethal-dose virus challenge. *J. Virol.*, 67: 348-352, 1993.
49. Thomson, S.A., Elliott, S.L., Sherritt, M.A., Sproat, K.W., Coupar, B.E.H., Scalzo, A.A., Forbes, C.A., Ladhams, A.M., Mo, X.Y., Tripp, R.A., Doherty, P.C., Moss, D.J. Suhrbier, A. Recombinant polyepitope vaccines for the delivery of multiple cytotoxic T cell epitopes. *J. Immunol.*, 157: 822-826, 1996.
- 10 50. Juillard, V., Villefroy, P., Godfrin, D., Pavirani, A., Venet, A. Guillet, J.-G. Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. *Eur. J. Immunol.*, 25: 3467-3473, 1995.
- 20 51. Chen, P.W., Wang, M., Bronte, V., Zhai, Y., Rosenberg, S.A. Restifo, N.P. Therapeutic antitumor response after immunization with a recombinant adenovirus encoding a model tumor-associated antigen. *J. Immunol.*, 156: 224-231, 1996.
52. Zhai, Y., Yang, J.C., Kawakami, Y., Spiess, P., Wadsworth, S.C., Cardoza, L.M., Couture, L.A., Smith, A.E. Rosenberg, S.A. Antigen-specific tumor vaccines. Development and characterization of recombinant adenoviruses encoding MARTI and gp100 for cancer therapy. *J. Immunol.*, 156: 700-710, 1996.
- 25 53. Toes, R.E.M., Offringa, R., Blom, R.J.J., Melief, C.J.M. Kast, W.M. Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction. *Proc. Natl Acad. Sci. USA*, 93: 7855-7860, 1996.
- 30

SUBSTITUTE SHEET (RULE 26)

54. Toes, R.E.M., Blom, R.J.J., Offringa, R., Kast, W.M. Melief, C.J.M. Functional deletion of tumor-specific cytotoxic T lymphocytes induced by peptide immunization can lead to the inability to reject tumors. *J. Immunol.*, 156: 3911-3918, 1996.
- 5 55. Kast, W.M., Offringa, R., Peters, P.J., Voordouw, A.C., Meloen, R.H., Van der Eb, A.J. Melief, C.J.M. Eradication of adenovirus El-induced tumors by Ela-specific cytotoxic T lymphocytes. *Cell*, 59: 603-615, 1989.
56. Toes, R.E.M., Offringa, R., Blom, H.J.J., Brandt, R.M.P.,
10 Van der Eb, A.J., Melief, C.J.M. Kast, W.M. An adenovirus type 5 early region IB-encoded CTL epitope-mediating tumor eradication by CTL clones is down-modulated by an activated ras oncogene. *J. Immunol.*, 154: 3396-3405, 1995.
57. Feltkwnp, M.C.W., Vreugdenhil, G.R., Vierboom, M.P.M.,
15 Ras, E., Van der Burg, S.H., Ter Schegget, J., Mehef, C.J.M. Kast, W.M. CTL raised against a subdominant epitope offered as a synthetic peptide eradicate human papillomavirus type 16-induced tumors. *Eur.J. Immunol.*, 25: 2638-2641, 1995.
58. Fallaux, F.J., Kranenburg, O., Cramer, S.J., Houweling, A.,
20 A., Van Ormondt, H., Hoeben, R.C. Van der Eb, A.J. Characterization of 911: a new helper cell line for the titration and propagation of early region 1-deleted adenoviral vectors. *Hum. Gene Ther.*, 7: 215-222, 1996.
59. Mc Grory, W.J., Bautista, D.S. Graham, F.L. A simple
25 technique for the rescue of the early region I mutations into infectious human adenovirus type 5. *Virology*, 163: 614-617, 1988.
60. Traversari, C., Van der bruggen, P., Van den Eynde, B., Hainaut, P., Lemoine, C., Ohta, N., Old, L. Boon, T.
30 Transfection and expression of a gene coding for a human melanoma antigen recognized by autologous CTL. *Immunogenetics*, 35: 145-152., 1992.
61. Gausepohl, H., Kraft, M., Boulin, C. Frank, R.W. in (eds. Rivier, J.E. & Marshall, G.R.), *11th American peptide symposium*, ESCOM, Leiden, 1990, 1003-1004.
35

SUBSTITUTE SHEET (RULE 26)

62. Del Val, M., Schlicht, H.-J., Ruppert, T., Reddehase, M.J., Koszinowski, U. Efficient processing of an antigenic sequence for presentation by MHC class I molecules depends on its neighboring residues in the protein. *Cell*, 66: 1145-1153, 5 1991.
63. Ossendorp, F., Eggers, M., Neisig, A., Ruppert, T., Groettrup, M., Sijts, A., Mengedé, E., Kloetzel, P.-M., Neefjes, J., Koszinowski, U. Melief, C.J.M. A single residue exchange within a viral CTL epitope alters proteasome-mediated 10 degradation resulting in lack of antigen presentation. *Immunity*, 5:115-124, 1996.
64. Niedermann, G., Butz, S., Ihlenfeld, H.G., Grimm, R., Lucchiari, Hoschützky, H., Jung, G., Maier, B. Eichmann, K. Contribution of proteasome-mediated proteolysis to the 15 hierarchy of epitopes presented by major histocompatibility complex class I molecules. *Immunity*, 2: 289-299, 1995.
65. Dick, L.R., Aldrich, C., Jameson, S.C., Moomaw, C.R., Pramanik, B.C., Doyle, C.K., de Martino, G.N., Bevan, M.J., Forman, J.M. Slaughter, C.A. Proteolytic processing of 20 ovalbumin and β -galactosidase by the proteasome to yield antigenic peptides. *J. Immunol.*, 152: 3884-3894, 1994.
66. Boes, B., Hengel, H., Ruppert, T., Multhaupt, G., Koszinowski, U.H. Kloetzel, P.-M. Interferon stimulation modulates the proteolytic activity and cleavage site 25 preference of 20 S mouse proteasomes. *J. Exp. Med.*, 179: 901-909, 1994.
67. Cardozo, C., Vinitzky, A., Hidalgo, M.C., Michaud, C. Orłowski, M. A 3,4-dichloroisocoumarin-resistant component of multicatalytic proteinase complex. *Biochemistry*, 31: 7373- 30 7380, 1992.
68. Dick, L.R., Moonaw, C.R., De Martino, G.N. Slaughter, C.A. Degradation of oxidized insulin B chain by the multiproteinase complex macropain (proteasome). *Biochemistry*, 30: 2725-2734, 1991.
69. Ehring, B., Meyer, T. H., Eckerskom, C., Lottspeich, F. and Tampé, R. Effects of MHC-encoded subunits on the peptidase and proteolytic activities of human 20 Sproteasomes: Cleavage

SUBSTITUTE SHEET (RULE 26)

- of proteins and antigenic peptides. Eur. J. Biochemistry 235: 404-415, 1996.
70. Feltkamp, M.C.W., Smits, H.L., Vierboom, M.P.M., Minnaar, R.P., De Jongh, B.M., Drijfhout, J.W., Ter Schegget, J.,
5 Melief, C.J.M. Kast, W.M. Vaccination with a cytotoxic T lymphocyte epitope-containing peptide protects against a tumor induced by human Papillomavirus type 16-transformed cells. Eur. J. Immunol., 23: 2242-2249., 1993.
71. Rensing, M.E., Sette, A., Brandt, R.M.P., Ruppert, J.,
10 Wentworth, P.A., Hartman, M., Oseroff, C., Grey, H.M., Melief, C.J.M. Kast, W.M. Human CTL epitopes encoded by human papillomavirus type 16 E6 and E7 identified through in vivo and in vitro immunogenicity studies of HLA-A*0201 -binding peptides. J. Immunol., 154: 5934-5943, 1995.
- 15 72. Bednarek, M.A., Sauma, S.Y., Gammon, M.C., Porter, G., Tamhankar, S., Williamson, A.R. Zweerink, H.J. The minimum peptide epitope from the influenza virus matrix protein. Extra and intra-cellular loading of HLA-A2. J. Immunol., 147: 4047-4053, 1991.
- 20 73. Levrero M., Barban, V., Tiollais, P., Pefficaudet, M. Defective and non-defective adenovirus vectors for expressing foreign genes in vitro and in vivo. Gene 101: 195-202, 1991
74. Evan, G.I., Lewis, G.K., Ramsay, G. Bishop, M. Isolation of monoclonal antibodies specific for human c-Myc proto-
25 oncogene product. Mol.Cell.Biol. 5. 3610-3616, 1985.

TABLE 1 HPV 16 E6 and E7 peptides tested for binding in competition assay at different temperatures for different incubation times.

Sequence ^a	HPV16	IC ₅₀ ^b (nM)	Presence ^c of motif	4°C			26°C		
				3 hr	24 hr	3 hr	24 hr	3 hr	24 hr
				IC ₅₀ ^d (μM)	IC ₅₀ (μM)	IC ₅₀ (μM)	IC ₅₀ (μM)	IC ₅₀ (μM)	IC ₅₀ (μM)
HLA-A*0201									
TLGIVCP1	E7	7	+	3.9	0.7	6.5	3.1		
LLHGTGLIV	E7	8 / 208	+	20	5	10	6.9		
YMLDLQPETT	E7	46 / 33	+	2.9	0.7	11	7.3		
TLGIVCPIC	E7	153	+	>25	15.7	29	10		
KLPQLCTEL	E6	328 / 5556	+	>25	8.3	36	34.5		
AHFQDPQER	E6	1818 / >25000	+	>25	17.5	>50	>50		
LQTTIHDI1	E6	3157 / ~25000	+	>25	20.3	>50	>50		59
FIPSDGTPSY			+	0.8	0.4	1	1.1		
HLA-A*0301									
IVYRDGNPY	E6	10 / 660	+	2.1	0.8	2.5	2.5		
HLDKKKQRFH	E6	68	+	1.9	1.7	9	17		
AHFDQDPQER	E6	290	+	7.6	3.3	12.5	15		
TTLNQNYHK	E6	384	+	16.5	4.2	41	38		
IVCPIC50K	E7	1111	+	4.1	3.9	24	24		
AHSAARSSR	E6	4285 / 6600	+	4.3	4	6	7		
QQLLRREVV	E6	5000 / > 6600	+	17	>25	>50	>50		
KVFFPAI THK		/ 666	+	0.5	0.7	3	4		

SUBSTITUTE SHEET (RULE 26)

amino-acid sequence of the HPV peptides
binding capacity (IC_{50}) to the given HLA class I molecule as tested in the molecular binding assay [28]. For some peptides two IC_{50} values are given: HLA-A*0201, the value at the right of the backslash was reported in a later publication [29]; HLA-A*0301, the value at the right side was determined using a molecular binding assay which employs the same FL-labeled reference peptide as used in the cellular binding assay [Drijfhout, manuscript in preparation].
the presence of the HLA-A*0201 or HLA-A*0301 binding motif in the peptide
binding capacity of the peptides is shown as the concentration of peptide needed to inhibit binding of the FL-labeled peptide to 50% (IC_{50} in μM)
the non-labeled reference peptides, the slash means that their IC_{50} in the molecular binding assay is not known.

SUBSTITUTE SHEET (RULE 26)

TABLE II Binding capacity of known processed and presented peptides

Sequence ^a	IC ₅₀ ^b (nM)	IC ₅₀ ^c (μ M)	Origin	Reference
HLA-A*0201				
FLPSDFFPSV	2.8	0.4	hepatitis B nucleocapsid	30
GILGFVFTL	6	0.4	influenza A matrix	31
ILKEPVHGV	242	1.7	HIV-1 RT	32
SLYNTVATL	.	1.3	HIV-1 gag	33
YHNGTHSQV	.	1.7	tyrosinase	34
HLA-A*0301				
GVPLRPMTYK	11	0.5	HIV-1 nef	35
KLFNIMVTY	.	15	unknown	36
KLHKORAKS	.	12	unknown	36

^a amino-acid sequence of the peptides

^b binding capacity (IC₅₀ in nM) to the given HLA class I molecule as tested in the molecular binding assay [29]

^c binding capacity of the peptides in the present study is shown as the concentration of peptide needed to inhibit binding of the FL-labeled peptide to 50% (IC₅₀ in μ M)

**TABLE III Binding of conserved HIV-1 pol sequences
compliant with the HLA-A*0301 binding motif**

Sequence ^a	Position ^b	IC ₅₀ (μM) ^c
PISPIETVPVK	160 - 170	>100
PIETVPVKLK	163 - 172	>100
PIETVPVK	163 - 170	>100
PLTEEKIK	184 - 191	>100
AIKKKDSTK	221 - 229	1.0 - 3.0 *
GIPHPAGLK	252 - 260	0.3 - 0.5 *
SVTVLDVGDAY	264 - 274	>100
TVLDVGDAY	266 - 274	>100
VI DVGDAY	267 - 274	>100
NVLPQGWK	306 - 313	30.0 - 40.0
WMGYELHPDK	388 - 397	14.0 - 20.0
ELELAENR	459 - 466	>100
ELAENREILK	461 - 470	14.0 - 20.0
QLDCTHLEGK	781 - 790	8.5 - 10.0
AVHVASGY	795 - 802	21.5 - 25.0
QVRDQAEHLK	883 - 892	2.9 - 3.0 *
AVFIHNFKR	898 - 906	0.3 - 0.5 *
GIGGYSAGER	909 - 918	6.5 - 10.0
KIQNFRVYY	938 - 946	1.8 - 2.5 *
KIQNFRVY	938 - 945	70.0 - 90.0

^a The amino-acid sequence of conserved peptides derived from HIV-1

^b position of first and last amino-acid in HIV-1 polymerase derived from strain JR-CSF

^c Peptides were tested in the competition assay at 4°C with an incubation time of 24 hours.

The binding capacity of the peptides is shown as the range of the concentration of peptide needed to inhibit binding of the FL-labeled peptide to 50% (IC₅₀ in μM). The peptides that are marked with a asterisk (*) are considered to be potential CTL epitopes.

Table IV Comparison of the immunogenicity of Hepatitis B virus (HBV) or Human Papilloma virus type 16 (HPV16) derived peptides to the dissociation rate.

Peptide	amino-acid		Affinity		Immuno- genicity	Stability	
	position	Sequence	IC50 (nM)	IC50 (μ M)		(DT50%)	
HBV Pol ^a	635-643	GLYSSTVPV	33	4.5	+	> 4	hr
HBV Pol	1076-1084	HLYSHPIIL	38	8.0	+	> 4	hr
HBV Pol	1344-1352	WILRGTSFV	278	11.0	-	1	hr
HBV Pol	996-1004	NLSWLSLDV	385	6.0	+	3	hr
HBV Pol	992-1000	LLSSNLSWL	1087	19.5	-	1	hr
HBV Pol	985-993	NLQSLTNLL	2000	22.0	-	NS	
HBV Pol	43-51	HLLVGSSGL	2778	24.0	-	< 1	hr
HBV Pol	28-36	LLDDEAGPL	>25000	69.0	-	NS	
HBV Pol	594-602	PLEEELPRL	>25000	>100	-	NS	
HPV16 E7	86-93	TLGIVCPI	7	0.7	+	> 4	hr
HPV16 E7	11-20	YMLDLQPETT	46	0.7	+	> 4	hr
HPV16 E6	52-60	FAFRDLCIV	130	9.0	-	2	hr
HPV16 E7	7-15	TLHEYMLDL	188	5.0	-	2	hr
HPV16 E7	82-90	LLMGTLGIV	208	5.0	+	> 4	hr
HPV16 E6	18-26	KLPQLCTEL	328	8.5	-	2	hr
HPV16 E6	7-15	AMFQDPQER	1818	17.5	-	NS	
HPV16 E6	26-34	LQTTIHDII	3157	20.5	-	NS	

SUBSTITUTE SHEET (RULE 26)

Table IV

- a* Peptide origin, position of first and last amino-acid and amino-acid sequence and binding affinity as described previously (10,24).
- b* Affinity was measured as described recently (17). IC_{50} represents the amount of peptide required for 50% inhibition of binding of the fluorescein-labeled reference peptide to HLA-A*0201
- c* Immunogenicity of the peptide was determined by injection of peptide doses of 10- to 100-fold in excess of what is required to elicit optimal CTL responses emulsified in IFA together with an equimolar amount of I-A^b T-helper epitope (10,11): - non-immunogenic, + immunogenic
- d* The time required for 50% of the molecules to decay (DT50%) is given starting from $t = 2$ hours at 37°C. NS = non stable: < 10% of HLA molecules were detectable after a 2 hour incubation at 37°C.

SUBSTITUTE SHEET (RULE 26)

Table v Comparison of peptide binding affinity, dissociation rate and immunogenicity of HBV and HPV16 derived peptides.

Peptide binding affinity	<u>Dissociation rate DT50%</u>	
	≥ 3 hours	< 3 hours
high	3	0 immunogenic
	0	0 non-immunogenic
intermediate	3	0 immunogenic
	0	4 non-immunogenic
low	0	0 immunogenic
	0	7 non-immunogenic

SUBSTITUTE SHEET (RULE 26)

Table VI The stability of HLA-A*0201 complexed with known CTL epitopes.

Peptide	First aa position	Sequence	Affinity		Stability		Immunogenicity
			IC50 (μ M)		(DT50%)		
			<i>a</i>	<i>b</i>		<i>c</i>	<i>d</i>
HCV1 core	131	ADLMGYIPLV	50.0	> 4	hr		RC
HCV1 core	178	LLALLSCLTV	7.5	> 4	hr		RC
HCV1 NS3	1406	KLVALGINAV	5.0	4	hr		RC
HCV1 NS4	1789	SLMAFTAAV	1.5	> 4	hr		RC
HBV surface	335	WLSLLVPFV	1.0	> 4	hr		RC
HBV surface	348	GLSPTVWLSV	3.0	> 4	hr		RC
EBV LMP2	426	CLGGLLTMV	2.5	4	hr		PR1
HTLV1 tax	11	LLFGYPVYV	0.3	> 4	hr		RC
HPV11 E7	4	RLVTLKDIV	52.0	2	hr		PR2
INF B NP	85	KLGEFYNQMM	5.5	> 4	hr		CTL
INF A Matrix	58	GILGFVFTL	0.6	> 4	hr		CTL
HIV-1 Gag	76	SLYNTVATL	1.5	> 4	hr		CTL
HIV-1 Pol	267	VLDVGDYFSV	7.0	NS			PR3
HIV-1 Pol	468	ILKEPVHGV	8.0	> 4	hr		CTL
pmel17/gp100 [1]		YLEPGPVTA	8.5	4	hr		CTL
pmel17/gp100 [2]		LLDGTATLRL	5.5	4	hr		CTL
tyrosinase	369	YMNGTMSQV	4.5	> 4	hr		CTL

SUBSTITUTE SHEET (RULE 26)

Table VI

- a* Peptide origin, position of first amino-acid and amino-acid sequence of the different HLA-A *0201 restricted CTL epitopes are given (20,25-36).
- b* Binding affinity was measured as described recently (17). IC_{50} represents the amount of peptide required for 50% inhibition of binding of the fluorescein-labeled reference peptide to HLA-A *0201
- c* The time required for 50% of the molecules to decay (DT50%) is given starting from $t = 2$ hours at 37°C. NS = non stable, < 10% of HLA molecules were detectable after a 2 hour incubation at 37°C.
- d* *RC*: recall experiment wherein CTL already primed by viral infection of the patient in vivo were boosted in vitro with peptide to detect the precise epitope. All authors used similar protocols. *CTL*: peptides were used to identify the epitopes recognized by CTL which were obtained from patients. *PR1*: CTL were primed in vitro with an autologous EBV transformed B-cell line and then cloned, peptides were used to map the epitope recognized. *PR2*: CTL were induced in vitro using repeated stimulation with recombinant vaccinia virus-HPV11 E7 infected B-cells. *PR3*: CTL were induced in vitro using repetitive stimulation with peptide pulsed antigen presenting cells.

SUBSTITUTE SHEET (RULE 26)

Table VII Statistical analysis of the dissociation rate (DT50%) or binding affinity versus immunogenicity of HLA-A*0201 binding peptides.

	immunogenic	non-immunogenic
DT50% \geq 3 hr	21	0
DT50% < 3 hr	2	11
		$p=0.0000003$
high affinity	11	0
intermediate affinity	10	4
low affinity	2	7
		$p=0.0005$ ^b

^a) Fisher's 2-tailed exact test for 2 by 2 tables.

^b) The relation between binding affinity and immunogenicity was determined by comparison of the high-affinity binding peptides with the low-affinity binding peptides, using a Fisher's 2-tailed exact test for 2 by 2 tables.

SUBSTITUTE SHEET (RULE 26)

Table VII Statistical analysis of dissociation rate (DT50%) *or* binding affinity versus immunogenicity of peptides binding with intermediate- or low affinity to HLA-A*0201.

	immunogenic	non-immunogenic
DT50% \geq 3 hr	10	0
DT50% < 3 hr	2	11
		p=0.00007
intermediate affinity	10	4
low affinity	2	7
		p=0.04

* Fisher's 2-tailed exact test for 2 by 2 tables.

SUBSTITUTE SHEET (RULE 26)

Table VIII Immunogenicity of HIV-1 derived peptides with known dissociation rate tested in HLA-A*0201/Kb transgenic mice

Sequence+ origin		Affinity IC ₅₀ (μM)	Stability DT50%		LU30%/10 ⁶ cells	CTL response
		<i>a</i>	<i>b</i>	<i>c</i>	<i>d</i>	<i>e</i>
FLPSDDFPSV	HBVcore-18	0.4	> 4	hr	53 (25-71)	3/3
TLGIVCPI	HPV16E7-86	0.7	> 4	hr	183 (70-400)	3/3
VLDVGDAYFSV	HIV-1pol-267	7.0	NS		< 2	0/7
YMODLYVGSDL	HIV-1pol-343	8.0	i	hr	< 2	0/3
LLWKGEHAV	HIV-1pol-576	6.0	> 4	hr	84 (67-100)	2/3
ILKEPVHGV	HIV-1pol-468	8.0	> 4	hr	56 (17-100)	5/6

SUBSTITUTE SHEET (RULE 26)

Table VIII

- a* Peptide amino-acid sequence, protein and position of the first amino-acid of the different HLA-A*0201 binding potential CTL epitopes are given.
- b* Average binding affinity was measured as described recently (17). IC_{50} represents the amount of peptide required for 50% inhibition of binding of the fluorescein-labeled reference peptide to HLA-A*0201
- c* The time required for 50% of the molecules to decay (DT50%) is given starting from $t = 2$ hours at 37°C. NS = non stable: < 10% of HLA molecules were detectable after a 2 hour incubation at 37°C.
- d* Average of all mice and range of observed responses.
- e* Number of mice which mounted a peptide-specific CTL response per total mice vaccinated.

SUBSTITUTE SHEET (RULE 26)

Table IX: Relation between peptide binding affinity, stability of the MHC peptide complex and immunogenicity of the peptide.

	Peptide	source ¹	T2-assay F.I. ²	B cell assay IC50 ³	Stability assay DT50% in h. ⁴	Immuno- genicity ⁶
5						
	<u>Melan-A/MART-1-derived peptides</u>					
	EAAGIGILTV	aa26-35	0.58	15	NS ⁵	-
10	AAGIGILTV	aa 27-35	0.03	80	>4	+
	GILTVILGV	aa 31-39	0.95	6	>4	+
15	ALMDKSLHV	aa 56-64	0.96	7	>4	+
	<u>Positive control peptides</u>					
	GILGFVFTL	Flu-M1	1.35	0.6	>4	+
20	YLEPGPVTA	pmel17/gp100	0.93	8.5	4	+
	LLDGTATLRL	pmel17/gp100	0.69	4	4	+
25	YMDGTMSQV	tyrosinase	0.60	1.2	>4	+

SUBSTITUTE SHEET (RULE 26)

Legend to Table IX:

- 1) Protein sources from which peptides have been derived are mentioned. For Melan-A/Mart-1-derived peptides the respective aa positions are indicated. Positive control peptides have
5 been described elsewhere (40, 45-47).
- 2) Fluorescence index (F.I.) is calculated for binding of peptides to T2 cells at 25 µg/ml. The T2 binding assay has been described elsewhere (2).
- 3) Concentration of the peptide that inhibits 50% of maximal
10 binding of reference HBV core peptide. This binding assay employing MHC class I molecules on intact B cells is described under Example 1.
- 4) Relative stability of peptide binding to HLA-A*0201, calculated as DT50% see Example 2 for experimental
15 procedures).
- 5) NS = not stable; DT50% not calculated because of absence of peptide binding after 2 hrs.
- 6) Immunogenicity of peptide (see text Example 3).

SUBSTITUTE SHEET (RULE 26)

Table X

Preselected peptides having an amino acid sequence derived from human influenza M protein, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:

Peptide	Amino acid sequence	location in influenza M protein
10	1 S L L T E V E T Y V	(residues 2-11 of M protein)
	2 S L L T E V E T Y V L	(residues 2-12 of M protein)
	3 L L T E V E T Y V	(residues 3-11 of M protein)
	4 L L T E V E T Y V L	(residues 3-12 of M protein)
	5 V L M E W L K T R P I	(residues 41-51 of M protein)
15	6 P I L S P L T K G I	(residues 50-59 of M protein)
	7 I L S P L T K G I	(residues 51-59 of M protein)
	8 I L S P L T K G I L	(residues 51-60 of M protein)
	9 G I L G F V F T L	(residues 58-66 of M protein)
	10 G I L G F V F T L T V	(residues 58-68 of M protein)
20	11 I L G F V F T L T V	(residues 59-68 of M protein)
	12 R M G A V T T E V	(residues 134-142 of M protein)
	13 G L V C A T C E Q I A	(residues 145-155 of M protein)
	14 Q M V T T T N P L	(residues 164-172 of M protein)
	15 Q M V T T T N P L I	(residues 164-173 of M protein),

SUBSTITUTE SHEET (RULE 26)

The following table presents preselected peptides derived from human melanoma associated protein tyrosinase capable of upregulating HLA-A*0201 molecules on T2 cells.

5 Table XI

Peptide No.	Sequence	Residues
10	1	CLLWSFQ TSA 008-017
		LLWSFQ TSA 009-017
	2	RLLVRRNIFDL 116-126
		YLTAKHTI 137-145
15	3	TISSDYVIPI 144-153
		PAFLPWHRLFL 205-215
	4	FLPWHRLFL 207-215
		FLPWHRLFLL 207-216
	5	FLLRWEQEI 214-222
		TLEGFASPL 343-351
20	6	FASPLTGIADA 347-357
	7	SMHNALHIYM 361-370
	8	HIYMNGTMSQV 367-377
		YMNGTMSQV 369-377
	9	PIFLLHHAFV 384-393
		WLQRHRPLQEV 400-410
25	10	PLYRNGDFFI 431-440
	11	YIKSYLEQA 463-471
		RIWSWLLGA 473-481
		RIWSWLLGAAM 473-483
30	12	WLLGAAMVGA 477-486
	13	MVGAVLTAL 483-491
		VTALLAGPV 487-496
		LTALLAGPVSL 488-498
		TALLAGPVSL 489-499
		TALLAGPVSL 489-499
35	14	ALLAGPVSL 490-498
	15	ALLAGPVSL 490-499
	16	LLAGPVSL 491-499
		QLPEEKQPLL 506-515
40	17	LLMEKEDYHSL 514-524

SUBSTITUTE SHEET (RULE 26)

Table XII.

Preselected peptides having an amino acid sequence derived from p53, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group
 5 consisting of:

	Peptide	Amino acid sequence	location in human p53 protein
	1.	LLPENNVLS	(residues 25-33 of human p53)
	2.	RMPEAAPPV	(residues 65-73 of human p53)
	3.	FLHSGTAKSV	(residues 113-122 of human p53)
10	4.	KMFCQLAKT	(residues 132-140 of human p53)
	5.	KQSQHMTEV	(residues 164-172 of human p53)
	6.	HMTEVVRRC	(residues 168-176 of human p53)
	7.	DRNTFRHSVV	(residues 208-217 of human p53)
	8.	LLGRNSFEV	(residues 264-272 of human p53)
15	9.	KMLCQLAKT	(residues 132-140 of human p53)
	10.	NMFCQLAKT	(residues 132-140 of human p53)
	11.	KLFCQLAKT	(residues 132-140 of human p53)
	12.	QMFCQLAKT	(residues 132-140 of human p53)
	13.	KMFTQLAKT	(residues 132-140 of human p53)
20	14.	KMFYQLAKT	(residues 132-140 of human p53)
	15.	KMFCELAKT	(residues 132-140 of human p53)
	16.	KMFCQLAKY	(residues 132-140 of human p53)
	17.	NLFCQLAKT	(residues 132-140 of human p53)
	18.	QQSQHMTEV	(residues 164-172 of human p53)
25	19.	HMTEVLRRRC	(residues 168-176 of human p53)
	20.	HMTEVVRLC	(residues 168-176 of human p53)
	21.	HMTEVVRRF	(residues 168-176 of human p53)
	22.	HMTEVVRHC	(residues 168-176 of human p53)
	23.	DRNAFRHSVV	(residues 208-217 of human p53)
30	24.	DRNTFRHSMV	(residues 208-217 of human p53)
	25.	LLVRNSFEV	(residues 264-272 of human p53)
	26.	LLGRNSFEM	(residues 264-272 of human p53)
	A.	ILTIITLED	human p53 residues 251-259

SUBSTITUTE SHEET (RULE 26)

	B. MLSPDDIEQ	human p53 residues 44-52
	C. IRVEGNLRV	human p53 residues 195-203
	D. KLMFKTEGP	human p53 residues 382-390
	E. DLWKLLPEN	human p53 residues 21-29
5	F. ALPNTSSS	human p53 residues 307-315
	G. LHSGTAKSV	human p53 residues 114-122
	H. NLRKKGEPH	human p53 residues 288-297
	I. PLSSSVPSQ	human p53 residues 92-100
	J. ELPPGSTKR	human p53 residues 298-306
10	K. FLHSGTAKS	human p53 residues 113-121

SUBSTITUTE SHEET (RULE 26)

Preselected peptides having an amino acid sequence derived from HPV16/18 protein, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:

5

Table XIII.

Peptides derived from HPV16 proteins E6 and E7 binding to HLA-A2.1

10	Peptide No.	Amino acid sequence	protein (region)	SEQ NO
	-	AMFQDPQER	E6 (residues 7- 15)	1
	1	KLPQLCTEL	E6 (residues 18 - 26)	2
	2	QLCTELQTT	E6 (residues 21 - 29)	3
15	3	LCTELQTTI	E6 (residues 22 - 30)	4
	4	ELQTTIHDI	E6 (residues 25 - 33)	5
	5	LQTTIHDI	E6 (residues 26 - 34)	6
	6	TIHDIILEC	E6 (residues 29 - 37)	7
	7	IHDIILECV	E6 (residues 30 - 38)	8
20	8	CVYCKQQLL	E6 (residues 37 - 45)	9
	-	FAFRDLCIV	E6 (residues 52- 60)	10
	9	KISEYRHYC	E6 (residues 79 - 87)	11
	10	PLCDLLIRC	E6 (residues 102-110)	12
	11	TLHEYMLDL	E7 (residues 7 - 15)	13
25	12	YMLDLQPET	E7 (residues 11 - 19)	14
	13	MLDLQPETT	E7 (residues 12 - 20)	15
	14	RLCVQSTHV	E7 (residues 66 - 74)	16
	15	TLEDLLMGT	E7 (residues 78 - 86)	17
	16	LLMGTLGIV	E7 (residues 82 - 90)	18
30	17	GTLGIVCPI	E7 (residues 85 - 93)	19
	18	TLGIVCPIC	E7 (residues 86 - 94)	20

SUBSTITUTE SHEET (RULE 26)

TABLE XIV

Peptides derived from HPV18 proteins E6 and E7 binding to HLA-A2.

5	Peptide	Amino acid	protein (region)	SEQ
	No.	sequence		NO

10	1	KLPDLCTEL	E6 (residues 13 - 21)	21
	2	SLQDIEITC	E6 (residues 24 - 32)	22
	3	LQDIEITCV	E6 (residues 25 - 33)	23
	4	EITCVYCKT	E6 (residues 29 - 37)	24
	5	KTVLELTEV	E6 (residues 36 - 44)	25
15	6	ELTEVFEEA	E6 (residues 40 - 48)	26
	7	FAFKDLFVV	E6 (residues 47 - 55)	27
	8	DTLEKLTNT	E6 (residues 88 - 96)	28
	9	LTNTGLYNL	E6 (residues 93 -101)	29
	10	TLQDIVLHL	E7 (residues 7 - 15)	30
20	11	FQQLFLNTL	E7 (residues 86 - 94)	31
	12	QLFLNTLSF	E7 (residues 88 - 96)	32
	13	LFLNTLSFV	E7 (residues 89 - 97)	33
	14	LSFVCPWCA	E7 (residues 94 -102)	34

SUBSTITUTE SHEET (RULE 26)

TABLE XV

Peptides derived from HPV16 proteins E6 and E7 binding to HLA-A1

5	Amino acid sequence	protein (region)	SEQ NO

	YRDGNPYAV	E6 (residues 61- 69)	35
	WTGRCMSCC	E6 (residues 139-147)	36
	MSCCRSSRT	E6 (residues 144-152)	37
10	TTDLICYEQ	E7 (residues 19- 27)	38
	EIDGPAGQA	E7 (residues 37- 45)	39
	HVDIRTLED	E7 (residues 73- 81)	40

SUBSTITUTE SHEET (RULE 26)

TABLE XVI

Peptides derived from HPV16 proteins E6 and E7 binding to HLA-A3.2

5	Amino acid sequence	protein (region)	SEQ NO

	AMFQDPQER	E6 (residues 7- 15)	1
	IILECVYCK	E6 (residues 33- 41)	41
	CVYCKQQLL	E6 (residues 37- 45)	9
10	VYCKQQLLR	E6 (residues 38- 46)	42
	QQLLRREVY	E6 (residues 42- 50)	43
	IVYRDGNPY	E6 (residues 59- 67)	44
	YAVCDKCLK	E6 (residues 67- 75)	45
	AVCDKCLKF	E6 (residues 68- 76)	46
15	VCDKCLKFY	E6 (residues 69- 77)	47
	KFYISKISEY	E6 (residues 75- 83)	48
	KISEYRHYC	E6 (residues 79- 87)	11
	ISEYRHYCY	E6 (residues 80- 88)	49
	RHYCYSLYG	E6 (residues 84- 92)	50
20	SLYGTTLQ	E6 (residues 89- 97)	51
	TTLEQQYNK	E6 (residues 93-101)	52
	QQYNKPLCD	E6 (residues 97-105)	53
	LIRCINCQK	E6 (residues 107-115)	54
	HLDKKQRFH	E6 (residues 125-133)	55
25	CMSCCRSSR	E6 (residues 143-151)	56
	SCCRSSRTR	E6 (residues 145-153)	57
	CCRSSRTRR	E6 (residues 146-154)	58
	HYNIVTFCC	E7 (residues 51- 59)	59
	YNIVTFCCCK	E7 (residues 52- 60)	60
30	CCKCDSTLR	E7 (residues 58- 66)	61
	KCDSTLRLC	E7 (residues 60- 68)	62

SUBSTITUTE SHEET (RULE 26)

TABLE XVII

Peptides derived from HPV16 proteins E6 and E7 binding to HLA-A11

	Amino acid sequence	protein (region)	SEQ NO

	AMFQDPQER	E6 (residues 7- 15)	1
	IILECVYCK	E6 (residues 33- 41)	41
	CVYCKQQLL	E6 (residues 37- 45)	9
5	VYCKQQLLR	E6 (residues 38- 46)	42
	QQLLRREVY	E6 (residues 42- 50)	43
	IVYRDGNPY	E6 (residues 59- 67)	44
	YAVCDKCLK	E6 (residues 67- 75)	45
	AVCDKCLKF	E6 (residues 68- 76)	46
10	VCDKCLKFY	E6 (residues 69- 77)	47
	KISEYRHYC	E6 (residues 79- 87)	11
	ISEYRHYCY	E6 (residues 80- 88)	49
	LIRCINCQK	E6 (residues 107-115)	54
	TGRCMSCCR	E6 (residues 140-148)	63
15	CMSSCRSSR	E6 (residues 143-151)	56
	SSCRSSRTR	E6 (residues 145-153)	57
	HYNIVTFCC	E7 (residues 51- 59)	59
	YNIVTFCCCK	E7 (residues 52- 60)	60
	CCKCDSTLR	E7 (residues 58- 66)	61
20	VCPICSQKP	E7 (residues 90- 98)	64

SUBSTITUTE SHEET (RULE 26)

TABLE XVIII

Peptides derived from HPV16 proteins E6 and E7 binding to HLA-A24

5	Amino acid	protein (region)	SEQ
	sequence		NO

	MHQKRTAMF	E6 (residues 1- 9)	65
	LQTTIHDII	E6 (residues 26- 34)	6
10	VYCKQQLLR	E6 (residues 38- 46)	42
	LLRREVVYDF	E6 (residues 44- 52)	66
	VYDFAFRDL	E6 (residues 49- 57)	67
	PYAVCDKCL	E6 (residues 66- 74)	68
	KCLKFYSKI	E6 (residues 72- 80)	69
15	EYRHYCYSL	E6 (residues 82- 90)	70
	HYCYSLYGT	E6 (residues 85- 93)	71
	CYSLYGTTL	E6 (residues 87- 95)	72
	RFHNIRGRW	E6 (residues 131-139)	73
	RAHYNIVTF	E7 (residues 49- 57)	74

SUBSTITUTE SHEET (RULE 26)

Table XIX

Preselected peptides having an amino acid sequence derived from HIV, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:

1. E M M T A C Q G V
2. L L D T G A D D T V
- 10 3. V L D V G D A Y F S V
4. L L W K G E G A V
5. I L K E P V H G V

SUBSTITUTE SHEET (RULE 26)

Table XX.

Preselected peptides having an amino acid sequence derived from CEA, wherein said amino acid sequence has the ability to bind to human MHC Class I allele HLA-A2.1 and is selected from the group consisting of:

	Peptide no.	Amino acid sequence	Residues

10	A1	Q I I G Y V I G T	044-052
	A2	Y L W W V N N Q S L	142-151
	A3	V L Y G P D A P T I	199-208
	A4	V L Y G P D T P I	555-563
	A5	Y L S G A N L N L	571-579

15

Peptides derived from CEA binding to the HLA-A*0301 molecule

	Peptide no.	Amino acid sequence	Residues

	B1	H L F G Y S W Y K	027-035
	B2	R V D G N R Q I I G Y	038-048
	B3	R V Y P E L P K	105-112
25	B4	R L Q L S N D N R	334-342
	B5	E L F I S N I T E K	427-436
	B6	L F I S N I T E K	428-436
	B7	F I S N I T E K	429-436
	B8	T L T L F N V T R	521-529
30	B9	T L F N V T R N D A R	523-533
	B10	N V T R N D A R	526-533
	B11	F V S N L A T G R	622-630

SUBSTITUTE SHEET (RULE 26)

Table A the oligonucleoties used in these studies in order to generate rAdV that encoded CTL epitopes in a string-of-bead fashion, linked with proteolytic cleavage sites that direct CTL epitope processing.

5	1a	CGCGAATTATGAACGCGTC
	1b	GTACGACGCGTRCATAATT
	2a	GTACGCTACTAGTGAACAGAAGCTGATATCAGAGGAAGACCTAAACTGAT
10	2b	CTAGATCAGTTTAGG CWMATATCAGCTTCTGTTCCTAGTAGC
	3a	CGCGGCAGCTTCCGGTCCTTCTAACACACCTCCTGAGATAGCAGCC
	3b	GCTATCTCAGGAGGTGTGTTAGAAGGACCGGAAGCTGC
15	4a	CTGTAAATATCAGGAATTGTTGCTACATTGCAGCTG
	4b	CTAGCAGCTGCAATGTAGCAACAATTCCTGATATTTACAGCTGC
	5a	CGCGGCAGCTACACTAGGAATTGTGTGCCCCATCGCAGCC
	5b	GCGATGGGGCACACAATTCCTAGTGTAGCTGC
20	6a	GCTAGAGCCCATTACAATATTGTAACCTTTGCTGCG
	6b	GCAAAGGTTACAATATTGTAATGGGCTCTAGCGGCT
	7a	GCTGCCATCTACAAGAAGTCACAGCACATGGCTGCAG
25	7b	ACGCCGACGGTAGATGTTCTTCAGTGTCGTGTACCGA
	8a	GCTGGAATCCTAGGTTTCGTCTTTACGCTAGCTGCG
	8b	GCTAGAGTAAAGACGAAACCTAGGATTCCAGCGGCT
30	9a	GCTTATATGTTAGATTTGCAACCAGAGACAACTGCTGCAG
	9b	AGCAGTTGTCTCTGGTTGCAAATCTAACATATAAGCCGCA

SUBSTITUTE SHEET (RULE 26)

CLAIMS

1. A method for the selection of immunogenic T cell peptide epitopes present in polypeptide antigens comprising identification of peptides in the primary sequence of the antigen having a binding motif and size for binding to a HLA class I molecule, measuring the binding of said identified peptides to MHC class I molecules, whereby the stability of the complex of the peptide and the MHC class I molecule is measured on intact cells carrying said MHC class I molecule at their surfaces.
2. A method according to claim 1 whereby the intact cells are B cells.
3. A method according to claim 2 whereby the B cells are human B cells.
4. A method according to any one of the foregoing claims comprising a further selection step of peptides whereby the peptides and their flanking sequences in the intact antigen are screened for compliance with the rules for proteasome cleavage of natural polypeptides sequences.
5. A method according to any one of the foregoing claims whereby the peptides and their flanking sequences in the intact antigen are screened for compliance with the rules for peptide transport and/or peptide loading onto HLA class I molecules.
6. A method according to any one of the foregoing claims further comprising a further binding assay for the binding of identified peptides to MHC class I molecules.
7. A method according to claim 6 wherein the further binding assay measures the binding of identified peptides to empty MHC class I molecules at the surface of an antigen processing defective cell line.
8. A method according to claim 7 wherein the processing defective cell line is the T2 cell line.
9. A method for the production of a vaccine for the treatment and/or prophylaxis of a disease associated with the

SUBSTITUTE SHEET (RULE 26)

- presence of a polypeptide antigen, comprising selecting T cell peptide epitopes of said polypeptide antigen by a method according to any one of claims 1-8, preparing selected peptide epitopes and mixing said peptide epitopes with a vehicle
5 suitable for administration.
10. A method for producing a vaccine according to claim 9 whereby an adjuvans is added to the vaccine.
11. A method according for producing a vaccine according to claim 9 or 10, whereby the peptide epitope comprises a
10 synthetic peptide.
12. A method according to claim 11 whereby the vaccine comprises a mixture of different synthetic peptides.
13. A method according to claim 11 or 12 whereby the synthetic peptide is loaded onto a dendritic cell.
- 15 14. A method according to anyone of claims 9-12, whereby the peptide epitopes are present in a string-bead conformation.
15. A method according to claim 14 whereby the strings comprises proteolytic cleavage sites.
16. A method according to claim 9 or 10 whereby a peptide
20 epitope is provided as part of a recombinant protein.
17. A method according to claim 16 whereby the recombinant protein has a string bead conformation whereby the beads are peptide epitopes.
18. A method according to claim 17 whereby the strings
25 comprise proteolytic cleavage sites.
19. A method according to any one of claims 16-18 whereby the recombinant protein is loaded on a dendritic cell.
20. A recombinant protein comprising a peptide epitope selected according to a method of anyone of claims 1-8.
- 30 21. A recombinant protein according to claim 20 which protein has a string-bead conformation wherein the beads are peptide epitopes selected according to a method of anyone of claims 1-8.
22. A recombinant protein according to claim 21 whereby
35 strings comprise proteolytic cleavage sites.
23. A recombinant nucleic acid molecule encoding a recombinant protein according to anyone of claims 20-22.

SUBSTITUTE SHEET (RULE 26)

24. A recombinant nucleic acid according to claim 23 which is a recombinant Canary pox virus nucleic acid.
25. A recombinant nucleic acid according to claim 23 which is a recombinant human adenovirus nucleic acid.
- 5 26. A recombinant Canary pox virus comprising a nucleic acid according to claim 24 and/or which comprises a recombinant protein encoded by said nucleic acid.
27. A recombinant human adenovirus comprising a nucleic acid according to claim 25 and/or which comprises a recombinant
- 10 protein encoded by said nucleic acid.

SUBSTITUTE SHEET (RULE 26)

1/14




FIG. 1

2/14




FIG. 2

3/14




FIG. 3

4/14




FIG. 4

5/14




FIG. 5

6/14




FIG. 6

7/14





FIG. 7


Recombinant Adenoviruses carrying 'string bead' minigenes



8/14

Figure 8

CTL epitopes encoded by string-bead minigene 1
are processed and presented to tumor-specific CTL



CTL epitopes encoded by string-bead minigene 2
are processed and presented to tumor-specific CTL




Figure 10

**CTL epitopes encoded by rAd in a string-bead fashion
are processed and presented to tumor-specific CTL**




Figure 11

12/14

Ad5E1-specific CTL immunity induced by vaccination with rAd-1 or rAd-2




Figure 12

HPV16 E7-specific, H-2^b-restricted CTL immunity induced by vaccination with rAd-1




Figure 13

Vaccination with rAd-1 induces protective immunity against Ad5E1A + ras tumors




Figure 14

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/NL 97/00229

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 G01N33/569 G01N33/557 A61K39/00 C07K14/00 C12N15/00
C12N15/83

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N A61K C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	NATURE (LONDON) (1994), 371(6494), 250-2 CODEN: NATUAS;ISSN: 0028-0836, XP000604820 NELSON, CHRISTOPHER A. ET AL: "Peptides determine the lifespan of MHC class II molecules in the antigen-presenting cell" see page 250, left-hand column, line 12 - line 19 see page 250, left-hand column, line 28 - line 32 see page 250, right-hand column, line 1-3 see page 252, left-hand column, line 6 - line 10 see table 2	1-27
X	WO 94 26785 A (US HEALTH) 24 November 1994 see claim 1 --- -/--	20-27

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- "&" document member of the same patent family

Date of the actual completion of the international search

8 September 1997

Date of mailing of the international search report

3 0 -09- 1997

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Hoekstra, S

INTERNATIONAL SEARCH REPORT

Internat Application No
PCT/NL 97/00229

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	THE JOURNAL OF IMMUNOLOGY, vol. 156, no. 9, 1 May 1996, pages 1308-1314, XP002040034 VAN DER BURG, S.H., ET AL.: "Immunogenecity of peptides bound to MHC Class I Molecules depends on the MHC-peptide Complex stability" see the whole document ---	1-27
P,X	THE JOURNAL OF IMMUNOLOGY, vol. 157, 1996, pages 822-826, XP002039433 THOMSON, S.A. ET AL.: "Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T Cell epitopes." see the whole document ---	12-19
X	JOURNAL OF VIROLOGY, vol. 67, no. 1, 1 January 1993, pages 348-352, XP000674226 WHITTON J L ET AL: "A "STRING-OF-BEADS" VACCINE, COMPRISING LINKED MINIGENES, CONFERS PROTECTION FROM LETHAL-DOSE VIRUS CHALLENGE" see the whole document ---	12-19
Y	WO 95 09642 A (LUDWIG INST CANCER RES) 13 April 1995 see page 4, line 16 - page 4, line 30 ---	1-27
Y	JOURNAL OF IMMUNOLOGY, vol. 149, no. 11, 1 December 1992, pages 3580-3587, XP000371892 PARKER K C ET AL: "SEQUENCE MOTIFS IMPORTANT FOR PEPTIDE BINDING TO THE HUMAN MHC CLASS I MOLECULE, HLA-A2" see the whole document ---	1-27
Y	WO 94 21287 A (US HEALTH) 29 September 1994 see the whole document ---	13
E	WO 96 22067 A (UNITED BIOMEDICAL INC) 25 July 1996 see the whole document ---	9-27
A	IMMUNOGENETICS (1995), 42(5), 392-7 CODEN: IMNGBK;ISSN: 0093-7711, XP000603776 DAVENPORT, MILES P. ET AL: "An empirical method for the prediction of T-cell epitopes" see the whole document ---	1-27

-/--

INTERNATIONAL SEARCH REPORT

Internat. Application No.
PCT/NL 97/00229

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ACTA CRYSTALLOGR., SECT. D: BIOL. CRYSTALLOGR. CODEN: ABCRE6;ISSN: 0907-4449, vol. D51, no. 4, 1995, pages 541-549, XP000603826 SCAPOZZA, LEONARDO ET AL: "Molecular dynamics and structure-based drug design for predicting non-natural nonapeptide binding to a class I MHC protein" see the whole document ---	1-27
A	MOLECULAR IMMUNOLOGY, vol. 31, no. 11, 1994, pages 813-822, XP000603774 A. SETTE ET AL.: "peptide binding to the most frequent HL-A Class I alleles measured by quantitative molecular binding assays" see the whole document ---	1-27
A	JOURNAL OF IMMUNOTHERAPY, vol. 14, no. 2, 1993, pages 121-126, XP002015226 NIJMAN, H.W. ET AL.: "Characterization of Cytotoxic T lymphocyte epitopes of a self-protein, p53 and a non-self-protein, influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides." see the whole document ---	1-27
A	HUMAN IMMUNOLOGY, vol. 43, no. 1, May 1995, pages 13-18, XP000603786 D'AMARO, J. ET AL.: "A computer Program for predicting possible Cytotoxic T lymphocyte epitopes based on HLA Class I Peptide-binding motifs" see the whole document -----	1-27

Form PCT/ISA/210 (continuation of second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NL 97/00229

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9426785 A	24-11-94	AU 7017394 A EP 0701572 A JP 9500614 T	12-12-94 20-03-96 21-01-97
WO 9509642 A	13-04-95	AU 7958994 A	01-05-95
WO 9421287 A	29-09-94	AU 6363094 A CA 2158281 A EP 0692973 A	11-10-94 29-09-94 24-01-96
WO 9622067 A	25-07-96	AU 5849796 A	07-08-96

Form PCT/ISA/210 (patent family annex) (July 1992)

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☒ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.